https://trial.medpath.com/news/youth-associated-protein-timp2-rejuvenates-brain-immune-cells-in-aged-mice 2026-08-15T21:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/youth-associated-protein-timp2-rejuvenates-brain-immune-cells-in-aged-mice 2026-08-15T21:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/problematic-drug-use-in-israel-surges-post-october-7-with-sedatives-and-opioids-showing-steepest-increases 2026-08-15T21:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/problematic-drug-use-in-israel-surges-post-october-7-with-sedatives-and-opioids-showing-steepest-increases 2026-08-15T21:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/newer-blood-thinners-noacs-may-slow-cognitive-decline-in-alzheimer-s-patients-with-atrial-fibrillation 2026-08-15T20:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/newer-blood-thinners-noacs-may-slow-cognitive-decline-in-alzheimer-s-patients-with-atrial-fibrillation 2026-08-15T20:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/oral-upadacitinib-shows-promise-for-restoring-skin-colour-in-non-segmental-vitiligo 2026-08-15T20:47:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oral-upadacitinib-shows-promise-for-restoring-skin-colour-in-non-segmental-vitiligo 2026-08-15T20:47:58+00:00 hourly 0.9 https://trial.medpath.com/news/madrid-hospital-creates-first-bone-metamaterial-prosthesis-preventing-leg-amputation 2026-08-15T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/madrid-hospital-creates-first-bone-metamaterial-prosthesis-preventing-leg-amputation 2026-08-15T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/rnai-therapeutics-expand-beyond-the-liver-as-sirna-drug-development-accelerates 2026-08-15T19:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rnai-therapeutics-expand-beyond-the-liver-as-sirna-drug-development-accelerates 2026-08-15T19:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/lab-grown-mini-guts-bring-personalised-ibd-treatment-for-children-a-step-closer 2026-08-15T19:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lab-grown-mini-guts-bring-personalised-ibd-treatment-for-children-a-step-closer 2026-08-15T19:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/kmtpa-and-yanolja-research-sign-mou-to-build-an-integrated-k-medical-wellness-tourism-ecosystem 2026-08-15T17:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kmtpa-and-yanolja-research-sign-mou-to-build-an-integrated-k-medical-wellness-tourism-ecosystem 2026-08-15T17:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/polyu-develops-ai-virtual-patient-simulation-system-for-precision-cancer-care 2026-08-15T17:47:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/polyu-develops-ai-virtual-patient-simulation-system-for-precision-cancer-care 2026-08-15T17:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/aizen-therapeutics-inks-multi-program-deal-to-advance-oral-biologics-with-dax-ai-platform 2026-08-15T16:48:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aizen-therapeutics-inks-multi-program-deal-to-advance-oral-biologics-with-dax-ai-platform 2026-08-15T16:48:50+00:00 hourly 0.9 https://trial.medpath.com/news/nfl-s-nazeeh-johnson-suspended-six-games-after-positive-ped-test-tied-to-fertility-drug-clomid 2026-08-15T16:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nfl-s-nazeeh-johnson-suspended-six-games-after-positive-ped-test-tied-to-fertility-drug-clomid 2026-08-15T16:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/hydrocolloid-patches-from-acne-treatment-to-blister-care-the-science-behind-a-beauty-staple 2026-08-15T16:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hydrocolloid-patches-from-acne-treatment-to-blister-care-the-science-behind-a-beauty-staple 2026-08-15T16:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/thbs1-macrophages-drive-an-immunosuppressive-tumor-microenvironment 2026-08-15T16:48:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thbs1-macrophages-drive-an-immunosuppressive-tumor-microenvironment 2026-08-15T16:48:03+00:00 hourly 0.9 https://trial.medpath.com/news/belzutifan-plus-lenvatinib-improves-disease-control-in-previously-treated-advanced-renal-cell-carcinoma 2026-08-15T15:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belzutifan-plus-lenvatinib-improves-disease-control-in-previously-treated-advanced-renal-cell-carcinoma 2026-08-15T15:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/cct7-expression-emerges-as-a-prognostic-marker-in-lung-adenocarcinoma 2026-08-15T15:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cct7-expression-emerges-as-a-prognostic-marker-in-lung-adenocarcinoma 2026-08-15T15:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/michigan-confirms-human-h1n2v-swine-flu-case-in-fair-exhibitor 2026-08-15T14:48:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/michigan-confirms-human-h1n2v-swine-flu-case-in-fair-exhibitor 2026-08-15T14:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/candel-therapeutics-advances-can-2409-toward-bla-submission-targeting-first-commercial-product-in-2027 2026-08-15T13:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candel-therapeutics-advances-can-2409-toward-bla-submission-targeting-first-commercial-product-in-2027 2026-08-15T13:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/natco-pharma-q1-profit-slumps-57-on-lenalidomide-sales-erosion-plans-2000-crore-qip-for-acquisitions 2026-08-15T10:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natco-pharma-q1-profit-slumps-57-on-lenalidomide-sales-erosion-plans-2000-crore-qip-for-acquisitions 2026-08-15T10:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/stopping-myopia-treatment-safely-understanding-and-managing-the-rebound-effect 2026-08-15T07:50:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stopping-myopia-treatment-safely-understanding-and-managing-the-rebound-effect 2026-08-15T07:50:01+00:00 hourly 0.9 https://trial.medpath.com/news/sumitomo-pharma-america-doses-first-patient-in-phase-1-2a-trial-of-ipsc-derived-cell-therapy-dsp-3077-for-retinitis-pigmentosa 2026-08-15T07:49:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sumitomo-pharma-america-doses-first-patient-in-phase-1-2a-trial-of-ipsc-derived-cell-therapy-dsp-3077-for-retinitis-pigmentosa 2026-08-15T07:49:57+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-profiling-of-high-risk-pediatric-tumors-reveals-actionable-alterations-in-nearly-one-quarter-of-patients 2026-08-15T03:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomic-profiling-of-high-risk-pediatric-tumors-reveals-actionable-alterations-in-nearly-one-quarter-of-patients 2026-08-15T03:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-wins-fda-accelerated-approval-for-zenbexus-its-first-celmod-therapy-for-multiple-myeloma 2026-08-15T01:47:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-wins-fda-accelerated-approval-for-zenbexus-its-first-celmod-therapy-for-multiple-myeloma 2026-08-15T01:47:37+00:00 hourly 0.9 https://trial.medpath.com/news/automated-mri-pipeline-improves-evaluation-of-experimental-stroke-therapies-across-multicenter-preclinical-studies 2026-08-15T01:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/automated-mri-pipeline-improves-evaluation-of-experimental-stroke-therapies-across-multicenter-preclinical-studies 2026-08-15T01:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/wolfe-research-upgrades-abbott-labs-and-abbvie-to-outperform-amid-in-line-inflation-data 2026-08-15T00:48:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wolfe-research-upgrades-abbott-labs-and-abbvie-to-outperform-amid-in-line-inflation-data 2026-08-15T00:48:14+00:00 hourly 0.9 https://trial.medpath.com/news/appeals-court-sides-with-trump-in-fight-over-subpoena-of-gender-affirming-care-provider 2026-08-14T23:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/appeals-court-sides-with-trump-in-fight-over-subpoena-of-gender-affirming-care-provider 2026-08-14T23:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-human-trials-of-chemogenetic-dreadd-therapies-in-china-stun-us-neuroscientists 2026-08-14T23:47:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-human-trials-of-chemogenetic-dreadd-therapies-in-china-stun-us-neuroscientists 2026-08-14T23:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-research-horizons-charity-capital-model-targets-broken-childhood-cancer-market-after-1-5b-myricx-exit 2026-08-14T23:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-research-horizons-charity-capital-model-targets-broken-childhood-cancer-market-after-1-5b-myricx-exit 2026-08-14T23:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/speed-of-light-the-astro-foundation-awards-2-4-million-to-accelerate-radiation-medicine-research 2026-08-14T23:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/speed-of-light-the-astro-foundation-awards-2-4-million-to-accelerate-radiation-medicine-research 2026-08-14T23:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/prescription-drug-prices-fall-3-1-year-over-year-in-july-steepest-decline-in-over-60-years 2026-08-14T23:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prescription-drug-prices-fall-3-1-year-over-year-in-july-steepest-decline-in-over-60-years 2026-08-14T23:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/leonabio-on-track-to-complete-phase-3-elaine-3-enrollment-for-lasofoxifene-in-esr1-mutated-metastatic-breast-cancer-in-4q-2026 2026-08-14T22:56:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leonabio-on-track-to-complete-phase-3-elaine-3-enrollment-for-lasofoxifene-in-esr1-mutated-metastatic-breast-cancer-in-4q-2026 2026-08-14T22:56:13+00:00 hourly 0.9 https://trial.medpath.com/news/summer-covid-19-surge-rises-again-across-the-us-though-milder-than-prior-waves 2026-08-14T21:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summer-covid-19-surge-rises-again-across-the-us-though-milder-than-prior-waves 2026-08-14T21:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-properties-acquires-former-pfizer-seagen-biomanufacturing-facility-in-everett-for-78-million 2026-08-14T20:56:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-properties-acquires-former-pfizer-seagen-biomanufacturing-facility-in-everett-for-78-million 2026-08-14T20:56:50+00:00 hourly 0.9 https://trial.medpath.com/news/abdominal-obesity-combined-with-vitamin-d-deficiency-more-than-doubles-death-risk-after-age-50 2026-08-14T20:56:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abdominal-obesity-combined-with-vitamin-d-deficiency-more-than-doubles-death-risk-after-age-50 2026-08-14T20:56:28+00:00 hourly 0.9 https://trial.medpath.com/news/vivosim-labs-ai-powered-3d-tissue-models-report-91-liver-toxicity-accuracy-amid-fda-nam-momentum 2026-08-14T20:56:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vivosim-labs-ai-powered-3d-tissue-models-report-91-liver-toxicity-accuracy-amid-fda-nam-momentum 2026-08-14T20:56:09+00:00 hourly 0.9 https://trial.medpath.com/news/placental-biology-breakthrough-could-make-biologic-medicines-safer-during-pregnancy 2026-08-14T20:55:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/placental-biology-breakthrough-could-make-biologic-medicines-safer-during-pregnancy 2026-08-14T20:55:45+00:00 hourly 0.9 https://trial.medpath.com/news/federal-ban-on-intoxicating-hemp-products-reshapes-risk-and-coverage-for-cannabis-industry 2026-08-14T20:54:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-ban-on-intoxicating-hemp-products-reshapes-risk-and-coverage-for-cannabis-industry 2026-08-14T20:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/new-miniature-microscope-watches-and-controls-individual-brain-cells-during-natural-movement 2026-08-14T20:53:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-miniature-microscope-watches-and-controls-individual-brain-cells-during-natural-movement 2026-08-14T20:53:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-lantheus-tauklarify-pet-imaging-agent-for-alzheimer-s-assessment 2026-08-14T20:53:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-lantheus-tauklarify-pet-imaging-agent-for-alzheimer-s-assessment 2026-08-14T20:53:43+00:00 hourly 0.9 https://trial.medpath.com/news/most-americans-still-believe-outdated-antibiotic-guidance-study-finds 2026-08-14T20:53:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/most-americans-still-believe-outdated-antibiotic-guidance-study-finds 2026-08-14T20:53:42+00:00 hourly 0.9 https://trial.medpath.com/news/quitting-alcohol-changes-the-brain-and-may-prime-it-for-relapse-mouse-study-finds 2026-08-14T20:53:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quitting-alcohol-changes-the-brain-and-may-prime-it-for-relapse-mouse-study-finds 2026-08-14T20:53:41+00:00 hourly 0.9 https://trial.medpath.com/news/ema-revokes-avacopan-tavneos-after-gcp-breaches-in-advocate-trial-as-fda-hearing-looms 2026-08-14T20:53:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-revokes-avacopan-tavneos-after-gcp-breaches-in-advocate-trial-as-fda-hearing-looms 2026-08-14T20:53:36+00:00 hourly 0.9 https://trial.medpath.com/news/nanochon-receives-panama-regulatory-approval-to-initiate-first-in-human-study-of-chondrografttm-for-knee-cartilage-defects 2026-08-14T20:53:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanochon-receives-panama-regulatory-approval-to-initiate-first-in-human-study-of-chondrografttm-for-knee-cartilage-defects 2026-08-14T20:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/transcell-biologics-and-space-cargo-unlimited-partner-to-test-drugs-and-vaccines-on-human-mps-models-in-orbital-microgravity 2026-08-14T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcell-biologics-and-space-cargo-unlimited-partner-to-test-drugs-and-vaccines-on-human-mps-models-in-orbital-microgravity 2026-08-14T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/massachusetts-retailers-sue-to-block-emergency-kratom-ban-as-schedule-i-order-nears-effective-date 2026-08-14T16:51:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massachusetts-retailers-sue-to-block-emergency-kratom-ban-as-schedule-i-order-nears-effective-date 2026-08-14T16:51:28+00:00 hourly 0.9 https://trial.medpath.com/news/aging-as-a-program-not-a-breakdown-new-theories-reframe-the-biology-of-growing-old 2026-08-14T16:50:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aging-as-a-program-not-a-breakdown-new-theories-reframe-the-biology-of-growing-old 2026-08-14T16:50:51+00:00 hourly 0.9 https://trial.medpath.com/news/skye-bioscience-to-acquire-redx-pharma-in-125m-financing-backed-deal-forming-fibrosis-focused-fibrx-therapeutics 2026-08-14T16:50:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/skye-bioscience-to-acquire-redx-pharma-in-125m-financing-backed-deal-forming-fibrosis-focused-fibrx-therapeutics 2026-08-14T16:50:40+00:00 hourly 0.9 https://trial.medpath.com/news/pexa-signs-7-5-msek-contract-with-top-10-global-pharma-for-ipf-clinical-study-using-pexa-2-1-systems 2026-08-14T16:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pexa-signs-7-5-msek-contract-with-top-10-global-pharma-for-ipf-clinical-study-using-pexa-2-1-systems 2026-08-14T16:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/trinity-biotech-secures-7-0-million-investment-from-perceptive-advisors-and-regains-nasdaq-compliance 2026-08-14T16:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trinity-biotech-secures-7-0-million-investment-from-perceptive-advisors-and-regains-nasdaq-compliance 2026-08-14T16:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/valisure-sues-u-s-pharmacopeia-over-claims-its-drug-testing-methods-are-unvalidated 2026-08-14T16:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/valisure-sues-u-s-pharmacopeia-over-claims-its-drug-testing-methods-are-unvalidated 2026-08-14T16:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/stair-climbing-tied-to-39-lower-cardiovascular-death-risk-in-meta-analysis-of-nearly-500000-adults 2026-08-14T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stair-climbing-tied-to-39-lower-cardiovascular-death-risk-in-meta-analysis-of-nearly-500000-adults 2026-08-14T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharma-completes-enrollment-in-phase-2-pynnacle-trial-plans-rezatapopt-nda-for-platinum-resistant-ovarian-cancer-in-q1-2027 2026-08-14T15:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmv-pharma-completes-enrollment-in-phase-2-pynnacle-trial-plans-rezatapopt-nda-for-platinum-resistant-ovarian-cancer-in-q1-2027 2026-08-14T15:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/cell-invisibility-cloak-could-enable-side-effect-free-diabetes-cell-therapy 2026-08-14T15:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-invisibility-cloak-could-enable-side-effect-free-diabetes-cell-therapy 2026-08-14T15:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-launches-industry-s-first-multi-agent-virtual-aging-cell-platform-centered-on-biological-age 2026-08-14T14:49:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-launches-industry-s-first-multi-agent-virtual-aging-cell-platform-centered-on-biological-age 2026-08-14T14:49:04+00:00 hourly 0.9 https://trial.medpath.com/news/sk-bioscience-submits-cta-to-south-africa-for-phase-1b-trial-of-rsv-preventive-antibody-rsm01 2026-08-14T14:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-bioscience-submits-cta-to-south-africa-for-phase-1b-trial-of-rsv-preventive-antibody-rsm01 2026-08-14T14:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/elevated-plasma-amyloid-b-1-40-linked-to-higher-postoperative-delirium-risk-after-cardiac-surgery 2026-08-14T14:48:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevated-plasma-amyloid-b-1-40-linked-to-higher-postoperative-delirium-risk-after-cardiac-surgery 2026-08-14T14:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/accountability-gaps-across-clinical-trial-contracts-undermine-study-execution 2026-08-14T14:47:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accountability-gaps-across-clinical-trial-contracts-undermine-study-execution 2026-08-14T14:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-tauklarify-florquinitau-f-18-pet-tracer-for-detecting-tau-pathology-in-alzheimer-s-disease 2026-08-14T13:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-tauklarify-florquinitau-f-18-pet-tracer-for-detecting-tau-pathology-in-alzheimer-s-disease 2026-08-14T13:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/covid-19-shifts-to-a-summer-phenomenon-as-cases-rise-across-the-us 2026-08-14T13:47:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/covid-19-shifts-to-a-summer-phenomenon-as-cases-rise-across-the-us 2026-08-14T13:47:42+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-of-epicor-yeast-postbiotic-triggers-rapid-selective-anti-inflammatory-cytokine-changes-in-healthy-adults 2026-08-14T13:47:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-of-epicor-yeast-postbiotic-triggers-rapid-selective-anti-inflammatory-cytokine-changes-in-healthy-adults 2026-08-14T13:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/finnish-study-links-habitual-coffee-consumption-to-leaner-body-composition-and-distinct-sex-hormone-signature 2026-08-14T12:54:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/finnish-study-links-habitual-coffee-consumption-to-leaner-body-composition-and-distinct-sex-hormone-signature 2026-08-14T12:54:10+00:00 hourly 0.9 https://trial.medpath.com/news/hdac-inhibition-turns-cancer-cell-quiescence-into-a-druggable-vulnerability-against-chemotherapy-resistant-ovarian-cancer 2026-08-14T11:48:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hdac-inhibition-turns-cancer-cell-quiescence-into-a-druggable-vulnerability-against-chemotherapy-resistant-ovarian-cancer 2026-08-14T11:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/arkbio-s-rsv-antiviral-ziresovir-receives-fda-approval-for-phase-ii-trial-in-critically-ill-infants 2026-08-14T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arkbio-s-rsv-antiviral-ziresovir-receives-fda-approval-for-phase-ii-trial-in-critically-ill-infants 2026-08-14T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/blood-pressure-management-for-stroke-patients-beyond-the-jsh-2025-guidelines 2026-08-14T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-pressure-management-for-stroke-patients-beyond-the-jsh-2025-guidelines 2026-08-14T11:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/snapchat-launches-multi-cta-ad-format-to-help-pharma-brands-run-compliant-in-feed-rx-promotions 2026-08-14T09:47:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/snapchat-launches-multi-cta-ad-format-to-help-pharma-brands-run-compliant-in-feed-rx-promotions 2026-08-14T09:47:34+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-trial-offers-first-hope-for-children-with-vanishing-white-matter-disease 2026-08-14T08:55:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-trial-offers-first-hope-for-children-with-vanishing-white-matter-disease 2026-08-14T08:55:30+00:00 hourly 0.9 https://trial.medpath.com/news/ancient-living-fossils-reveal-first-visual-evidence-of-how-complex-life-may-have-begun 2026-08-14T08:55:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ancient-living-fossils-reveal-first-visual-evidence-of-how-complex-life-may-have-begun 2026-08-14T08:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/pcf-and-bayer-launch-first-annual-va-medical-education-program-for-prostate-cancer-care 2026-08-14T07:47:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcf-and-bayer-launch-first-annual-va-medical-education-program-for-prostate-cancer-care 2026-08-14T07:47:35+00:00 hourly 0.9 https://trial.medpath.com/news/rilvegostomig-shows-durable-responses-in-checkpoint-inhibitor-resistant-nsclc-artemide-01-phase-i-ii-results 2026-08-14T03:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rilvegostomig-shows-durable-responses-in-checkpoint-inhibitor-resistant-nsclc-artemide-01-phase-i-ii-results 2026-08-14T03:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-launches-national-biobank-of-normal-tissues-from-deceased-donors-to-advance-precision-medicine 2026-08-14T03:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-launches-national-biobank-of-normal-tissues-from-deceased-donors-to-advance-precision-medicine 2026-08-14T03:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/pelthos-reports-45-revenue-growth-as-zelsuvmi-molluscum-launch-surpasses-30000-units-dispensed 2026-08-14T03:03:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pelthos-reports-45-revenue-growth-as-zelsuvmi-molluscum-launch-surpasses-30000-units-dispensed 2026-08-14T03:03:25+00:00 hourly 0.9 https://trial.medpath.com/news/immunocine-launches-tumor-preservation-program-and-expands-personalized-dendritic-cell-therapy-access 2026-08-14T03:02:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocine-launches-tumor-preservation-program-and-expands-personalized-dendritic-cell-therapy-access 2026-08-14T03:02:57+00:00 hourly 0.9 https://trial.medpath.com/news/managing-side-effects-of-modern-hiv-treatment-practical-strategies-and-emerging-long-acting-options 2026-08-14T01:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/managing-side-effects-of-modern-hiv-treatment-practical-strategies-and-emerging-long-acting-options 2026-08-14T01:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/aivita-biomedical-named-2026-prix-galien-usa-nominee-for-personalized-immunotherapy-platform 2026-08-14T00:48:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aivita-biomedical-named-2026-prix-galien-usa-nominee-for-personalized-immunotherapy-platform 2026-08-14T00:48:03+00:00 hourly 0.9 https://trial.medpath.com/news/maze-therapeutics-appoints-paula-johnson-and-sophie-kornowski-to-board-of-directors 2026-08-14T00:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maze-therapeutics-appoints-paula-johnson-and-sophie-kornowski-to-board-of-directors 2026-08-14T00:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/journey-medical-reports-23-revenue-growth-in-q2-2026-driven-by-emrosi-momentum-in-rosacea 2026-08-13T23:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/journey-medical-reports-23-revenue-growth-in-q2-2026-driven-by-emrosi-momentum-in-rosacea 2026-08-13T23:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/liver-s-internal-clock-governs-timed-release-of-metabolism-regulating-proteins-pointing-to-chronotherapy-for-metabolic-disease 2026-08-13T23:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liver-s-internal-clock-governs-timed-release-of-metabolism-regulating-proteins-pointing-to-chronotherapy-for-metabolic-disease 2026-08-13T23:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/patient-founded-fund-helps-medical-student-showcase-research-on-mental-health-burden-in-als 2026-08-13T22:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-founded-fund-helps-medical-student-showcase-research-on-mental-health-burden-in-als 2026-08-13T22:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/antipsychotic-adrs-affect-61-7-of-ugandan-psychiatric-outpatients-study-finds 2026-08-13T21:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/antipsychotic-adrs-affect-61-7-of-ugandan-psychiatric-outpatients-study-finds 2026-08-13T21:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/inhibrx-advances-ozekibart-toward-fda-decision-as-pfs-data-in-hnscc-looms 2026-08-13T21:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inhibrx-advances-ozekibart-toward-fda-decision-as-pfs-data-in-hnscc-looms 2026-08-13T21:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/uva-health-to-bring-nci-designated-comprehensive-cancer-care-to-lynchburg-this-fall 2026-08-13T20:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uva-health-to-bring-nci-designated-comprehensive-cancer-care-to-lynchburg-this-fall 2026-08-13T20:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/mosquito-bites-turned-into-immunity-boosters-wehi-and-msd-s-late-liver-stage-malaria-vaccination-approach 2026-08-13T20:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosquito-bites-turned-into-immunity-boosters-wehi-and-msd-s-late-liver-stage-malaria-vaccination-approach 2026-08-13T20:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/vinod-khosla-ai-is-creating-a-hyperabundance-of-new-drugs-but-testing-remains-18th-century 2026-08-13T20:47:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vinod-khosla-ai-is-creating-a-hyperabundance-of-new-drugs-but-testing-remains-18th-century 2026-08-13T20:47:50+00:00 hourly 0.9 https://trial.medpath.com/news/fewer-eclipse-related-eye-injuries-reported-after-uk-solar-eclipse-surgeon-says 2026-08-13T20:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fewer-eclipse-related-eye-injuries-reported-after-uk-solar-eclipse-surgeon-says 2026-08-13T20:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/bit-bio-launches-ioscreen-crispr-screening-platform-and-appoints-first-chief-technology-officer 2026-08-13T19:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bit-bio-launches-ioscreen-crispr-screening-platform-and-appoints-first-chief-technology-officer 2026-08-13T19:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/nova-scotia-invests-1-2-million-to-expand-verschuren-centre-s-precision-fermentation-biomanufacturing-capacity 2026-08-13T18:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nova-scotia-invests-1-2-million-to-expand-verschuren-centre-s-precision-fermentation-biomanufacturing-capacity 2026-08-13T18:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/nci-funded-study-targets-p-gp-to-reduce-mmae-induced-neuropathy-in-cancer-patients 2026-08-13T18:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nci-funded-study-targets-p-gp-to-reduce-mmae-induced-neuropathy-in-cancer-patients 2026-08-13T18:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/viral-rna-strategy-triples-mrna-lifespan-offering-path-to-longer-lasting-therapeutics 2026-08-13T17:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viral-rna-strategy-triples-mrna-lifespan-offering-path-to-longer-lasting-therapeutics 2026-08-13T17:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/poison-center-calls-for-xenobiotic-liver-injuries-surge-nearly-400-over-24-years 2026-08-13T17:48:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poison-center-calls-for-xenobiotic-liver-injuries-surge-nearly-400-over-24-years 2026-08-13T17:48:57+00:00 hourly 0.9 https://trial.medpath.com/news/khartis-therapeutics-emerges-from-stealth-with-95-million-to-advance-first-oral-selective-igf-1r-inhibitor-for-thyroid-eye-disease 2026-08-13T16:50:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/khartis-therapeutics-emerges-from-stealth-with-95-million-to-advance-first-oral-selective-igf-1r-inhibitor-for-thyroid-eye-disease 2026-08-13T16:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/union-county-spotlights-ohio-drug-recovery-court-with-over-50-success-rate 2026-08-13T16:50:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/union-county-spotlights-ohio-drug-recovery-court-with-over-50-success-rate 2026-08-13T16:50:01+00:00 hourly 0.9 https://trial.medpath.com/news/atrium-therapeutics-earns-15-million-milestone-payment-from-bristol-myers-squibb-for-second-lead-compound-in-cardiovascular-rna-collaboration 2026-08-13T16:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atrium-therapeutics-earns-15-million-milestone-payment-from-bristol-myers-squibb-for-second-lead-compound-in-cardiovascular-rna-collaboration 2026-08-13T16:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/genelux-case-report-details-16-7-month-pfs-in-platinum-relapsed-sclc-after-systemic-olvi-vec-plus-platinum-rechallenge 2026-08-13T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genelux-case-report-details-16-7-month-pfs-in-platinum-relapsed-sclc-after-systemic-olvi-vec-plus-platinum-rechallenge 2026-08-13T16:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/metabolic-epigenetic-immune-regulatory-networks-emerge-as-therapeutic-targets-in-inflammation-and-disease 2026-08-13T15:48:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolic-epigenetic-immune-regulatory-networks-emerge-as-therapeutic-targets-in-inflammation-and-disease 2026-08-13T15:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/mitochondrial-protein-opa1-deficiency-drives-sex-specific-fat-intake-and-obesity-study-finds 2026-08-13T15:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mitochondrial-protein-opa1-deficiency-drives-sex-specific-fat-intake-and-obesity-study-finds 2026-08-13T15:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/hippocratic-ai-launches-agentic-orchestrators-to-coordinate-voice-ai-teams-for-healthcare-outcomes 2026-08-13T15:47:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hippocratic-ai-launches-agentic-orchestrators-to-coordinate-voice-ai-teams-for-healthcare-outcomes 2026-08-13T15:47:59+00:00 hourly 0.9 https://trial.medpath.com/news/sirolimus-from-transplant-immunosuppressant-to-precision-therapeutic-across-rare-diseases-oncology-and-aging 2026-08-13T14:48:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sirolimus-from-transplant-immunosuppressant-to-precision-therapeutic-across-rare-diseases-oncology-and-aging 2026-08-13T14:48:09+00:00 hourly 0.9 https://trial.medpath.com/news/xanadu-and-university-of-alberta-partner-to-apply-quantum-computing-to-photodynamic-cancer-drug-discovery 2026-08-13T14:47:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xanadu-and-university-of-alberta-partner-to-apply-quantum-computing-to-photodynamic-cancer-drug-discovery 2026-08-13T14:47:39+00:00 hourly 0.9 https://trial.medpath.com/news/fentanyl-deaths-drop-22-as-administration-expands-prevention-and-enforcement-efforts 2026-08-13T14:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fentanyl-deaths-drop-22-as-administration-expands-prevention-and-enforcement-efforts 2026-08-13T14:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/alto-neuroscience-expands-alto-207-phase-3-program-in-treatment-resistant-depression-backed-by-100-million-financing 2026-08-13T13:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alto-neuroscience-expands-alto-207-phase-3-program-in-treatment-resistant-depression-backed-by-100-million-financing 2026-08-13T13:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/clover-health-delivers-first-full-year-profitability-trajectory-as-ai-powered-care-model-drives-48-membership-growth 2026-08-13T13:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clover-health-delivers-first-full-year-profitability-trajectory-as-ai-powered-care-model-drives-48-membership-growth 2026-08-13T13:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/canadians-cite-protecting-others-as-key-vaccine-motivator-yet-nearly-half-skipped-respiratory-vaccines-ahead-of-2026-2027-season 2026-08-13T12:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canadians-cite-protecting-others-as-key-vaccine-motivator-yet-nearly-half-skipped-respiratory-vaccines-ahead-of-2026-2027-season 2026-08-13T12:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/saudi-fda-launches-nadr-program-to-accelerate-rare-disease-drug-development 2026-08-13T12:48:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/saudi-fda-launches-nadr-program-to-accelerate-rare-disease-drug-development 2026-08-13T12:48:12+00:00 hourly 0.9 https://trial.medpath.com/news/seastar-medical-reports-82-quelimmune-revenue-growth-as-neutralize-aki-trial-advances-toward-adult-aki-indication 2026-08-13T12:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/seastar-medical-reports-82-quelimmune-revenue-growth-as-neutralize-aki-trial-advances-toward-adult-aki-indication 2026-08-13T12:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/aig-hospitals-and-johnson-johnson-partner-to-deploy-polyphonic-surgery-digital-ecosystem 2026-08-13T11:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aig-hospitals-and-johnson-johnson-partner-to-deploy-polyphonic-surgery-digital-ecosystem 2026-08-13T11:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/drugmakers-curb-swiss-reimbursement-applications-over-us-most-favoured-nation-pricing-policy 2026-08-13T11:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drugmakers-curb-swiss-reimbursement-applications-over-us-most-favoured-nation-pricing-policy 2026-08-13T11:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/orbusneich-reports-18-1-revenue-growth-and-advances-coronary-paclitaxel-dcb-trial-in-japan 2026-08-13T11:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orbusneich-reports-18-1-revenue-growth-and-advances-coronary-paclitaxel-dcb-trial-in-japan 2026-08-13T11:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-agrees-amt-130-data-can-support-accelerated-approval-in-huntington-s-disease-driving-uniqure-re-rating 2026-08-13T10:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-agrees-amt-130-data-can-support-accelerated-approval-in-huntington-s-disease-driving-uniqure-re-rating 2026-08-13T10:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/comprehensive-bmj-review-identifies-most-effective-bipolar-disorder-treatments-across-age-groups-and-mood-phases 2026-08-13T10:47:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comprehensive-bmj-review-identifies-most-effective-bipolar-disorder-treatments-across-age-groups-and-mood-phases 2026-08-13T10:47:30+00:00 hourly 0.9 https://trial.medpath.com/news/zipalertinib-plus-chemotherapy-meets-primary-endpoint-in-phase-3-rezilient3-trial-for-first-line-egfr-exon-20-insertion-nsclc 2026-08-13T07:48:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zipalertinib-plus-chemotherapy-meets-primary-endpoint-in-phase-3-rezilient3-trial-for-first-line-egfr-exon-20-insertion-nsclc 2026-08-13T07:48:41+00:00 hourly 0.9 https://trial.medpath.com/news/marcus-foundation-awards-28-7-million-to-advance-stem-cell-based-therapy-for-heart-attack-regeneration 2026-08-13T07:48:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marcus-foundation-awards-28-7-million-to-advance-stem-cell-based-therapy-for-heart-attack-regeneration 2026-08-13T07:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/pediatric-leucovorin-prescriptions-rose-sevenfold-in-2025-after-federal-officials-touted-it-for-autism 2026-08-13T07:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pediatric-leucovorin-prescriptions-rose-sevenfold-in-2025-after-federal-officials-touted-it-for-autism 2026-08-13T07:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/penitrium-targets-tumor-pseudo-resistance-as-first-prostate-cancer-patient-dosed-and-fda-clears-us-phase-2a 2026-08-13T04:47:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/penitrium-targets-tumor-pseudo-resistance-as-first-prostate-cancer-patient-dosed-and-fda-clears-us-phase-2a 2026-08-13T04:47:36+00:00 hourly 0.9 https://trial.medpath.com/news/talphera-s-nafamostat-gains-kdigo-endorsement-as-nephro-crrt-trial-nears-completion 2026-08-13T03:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/talphera-s-nafamostat-gains-kdigo-endorsement-as-nephro-crrt-trial-nears-completion 2026-08-13T03:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/six-australian-biomed-startups-share-a-13-5m-in-cureator-funding-round 2026-08-13T03:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/six-australian-biomed-startups-share-a-13-5m-in-cureator-funding-round 2026-08-13T03:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/an2-therapeutics-advances-three-phase-2-programs-as-boron-chemistry-pipeline-expands 2026-08-13T01:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/an2-therapeutics-advances-three-phase-2-programs-as-boron-chemistry-pipeline-expands 2026-08-13T01:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/jury-selection-begins-in-meta-s-federal-trial-over-youth-mental-health-harms 2026-08-13T00:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jury-selection-begins-in-meta-s-federal-trial-over-youth-mental-health-harms 2026-08-13T00:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/missouri-childhood-vaccine-rates-fall-below-herd-immunity-threshold-as-executive-order-seeks-to-cut-recommended-vaccines 2026-08-12T23:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/missouri-childhood-vaccine-rates-fall-below-herd-immunity-threshold-as-executive-order-seeks-to-cut-recommended-vaccines 2026-08-12T23:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/kras-g12c-from-undruggable-to-druggable-with-sotorasib-and-adagrasib 2026-08-12T23:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kras-g12c-from-undruggable-to-druggable-with-sotorasib-and-adagrasib 2026-08-12T23:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ctdna-clearance-and-mrd-may-identify-nsclc-patients-who-benefit-most-from-perioperative-nivolumab 2026-08-12T22:53:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ctdna-clearance-and-mrd-may-identify-nsclc-patients-who-benefit-most-from-perioperative-nivolumab 2026-08-12T22:53:14+00:00 hourly 0.9 https://trial.medpath.com/news/samsung-galaxy-buds-gain-fda-clearance-for-over-the-counter-hearing-aid-feature 2026-08-12T22:52:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/samsung-galaxy-buds-gain-fda-clearance-for-over-the-counter-hearing-aid-feature 2026-08-12T22:52:31+00:00 hourly 0.9 https://trial.medpath.com/news/dod-to-launch-three-year-pilot-covering-sperm-and-egg-freezing-for-deploying-service-members 2026-08-12T21:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dod-to-launch-three-year-pilot-covering-sperm-and-egg-freezing-for-deploying-service-members 2026-08-12T21:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/arrivent-advances-firmonertinib-toward-pivotal-egfr-exon-20-nsclc-data-as-adc-pipeline-progresses 2026-08-12T20:49:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrivent-advances-firmonertinib-toward-pivotal-egfr-exon-20-nsclc-data-as-adc-pipeline-progresses 2026-08-12T20:49:56+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-to-acquire-bla-stage-st-920-fabry-disease-gene-therapy-from-sangamo 2026-08-12T20:49:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-to-acquire-bla-stage-st-920-fabry-disease-gene-therapy-from-sangamo 2026-08-12T20:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/airplane-wastewater-surveillance-detects-sars-cov-2-variants-weeks-before-clinical-systems 2026-08-12T20:49:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/airplane-wastewater-surveillance-detects-sars-cov-2-variants-weeks-before-clinical-systems 2026-08-12T20:49:46+00:00 hourly 0.9 https://trial.medpath.com/news/royalty-pharma-and-zealand-pharma-enter-100-million-rusfertide-funding-agreement 2026-08-12T20:49:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royalty-pharma-and-zealand-pharma-enter-100-million-rusfertide-funding-agreement 2026-08-12T20:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-unveils-treatment-first-toolkit-linking-addiction-recovery-and-homelessness 2026-08-12T20:48:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-unveils-treatment-first-toolkit-linking-addiction-recovery-and-homelessness 2026-08-12T20:48:58+00:00 hourly 0.9 https://trial.medpath.com/news/proteomics-identifies-carboxypeptidase-e-as-a-potential-biomarker-for-synucleinopathies 2026-08-12T19:47:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomics-identifies-carboxypeptidase-e-as-a-potential-biomarker-for-synucleinopathies 2026-08-12T19:47:50+00:00 hourly 0.9 https://trial.medpath.com/news/manuka-honey-s-antibacterial-power-extends-beyond-sugar-and-mgo-aston-university-study-finds 2026-08-12T18:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/manuka-honey-s-antibacterial-power-extends-beyond-sugar-and-mgo-aston-university-study-finds 2026-08-12T18:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/oracle-expands-ai-across-healthcare-workflows-with-automated-coding-chart-review-and-dictation 2026-08-12T18:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oracle-expands-ai-across-healthcare-workflows-with-automated-coding-chart-review-and-dictation 2026-08-12T18:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/pcr-testing-improves-detection-of-fleaborne-typhus-in-los-angeles-county-extending-diagnostic-window-to-15-days 2026-08-12T18:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pcr-testing-improves-detection-of-fleaborne-typhus-in-los-angeles-county-extending-diagnostic-window-to-15-days 2026-08-12T18:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/pre-clinical-data-interpretation-requires-clinical-context-researchers-argue-in-nature-correspondence 2026-08-12T18:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pre-clinical-data-interpretation-requires-clinical-context-researchers-argue-in-nature-correspondence 2026-08-12T18:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/nejm-perspective-asks-whether-ai-can-say-i-don-t-know-as-llm-confabulation-rates-reach-99-6-on-fabricated-drug-names 2026-08-12T17:47:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nejm-perspective-asks-whether-ai-can-say-i-don-t-know-as-llm-confabulation-rates-reach-99-6-on-fabricated-drug-names 2026-08-12T17:47:50+00:00 hourly 0.9 https://trial.medpath.com/news/cancer-patients-face-steadily-longer-waits-to-begin-treatment-study-of-2-7-million-patients-finds 2026-08-12T17:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cancer-patients-face-steadily-longer-waits-to-begin-treatment-study-of-2-7-million-patients-finds 2026-08-12T17:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/bd-completes-enrollment-in-landmark-prevent-trial-evaluating-phasix-mesh-for-incisional-hernia-prevention 2026-08-12T17:47:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bd-completes-enrollment-in-landmark-prevent-trial-evaluating-phasix-mesh-for-incisional-hernia-prevention 2026-08-12T17:47:32+00:00 hourly 0.9 https://trial.medpath.com/news/mathematical-model-suggests-tapering-not-cycling-may-optimize-melanoma-targeted-therapy 2026-08-12T17:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mathematical-model-suggests-tapering-not-cycling-may-optimize-melanoma-targeted-therapy 2026-08-12T17:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/high-throughput-crispr-screening-emerges-as-key-tool-to-separate-causal-aging-regulators-from-correlative-markers 2026-08-12T16:51:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-throughput-crispr-screening-emerges-as-key-tool-to-separate-causal-aging-regulators-from-correlative-markers 2026-08-12T16:51:55+00:00 hourly 0.9 https://trial.medpath.com/news/rare-ventures-launches-a-25-million-venture-philanthropy-platform-to-accelerate-rare-disease-therapies 2026-08-12T16:50:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rare-ventures-launches-a-25-million-venture-philanthropy-platform-to-accelerate-rare-disease-therapies 2026-08-12T16:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/bridge-to-life-raises-110-million-to-make-hypothermic-oxygenated-perfusion-the-standard-of-care-in-liver-transplantation 2026-08-12T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bridge-to-life-raises-110-million-to-make-hypothermic-oxygenated-perfusion-the-standard-of-care-in-liver-transplantation 2026-08-12T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/news/elevated-serum-amyloid-p-component-identified-as-a-promising-biomarker-for-gestational-diabetes-mellitus 2026-08-12T16:49:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevated-serum-amyloid-p-component-identified-as-a-promising-biomarker-for-gestational-diabetes-mellitus 2026-08-12T16:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-ceo-seeks-new-deal-to-list-mounjaro-on-australia-s-pbs-amid-pricing-standoff 2026-08-12T15:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-ceo-seeks-new-deal-to-list-mounjaro-on-australia-s-pbs-amid-pricing-standoff 2026-08-12T15:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/noble-secures-u-s-patent-for-ai-powered-sound-detection-in-drug-delivery-and-diagnostic-devices 2026-08-12T15:48:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/noble-secures-u-s-patent-for-ai-powered-sound-detection-in-drug-delivery-and-diagnostic-devices 2026-08-12T15:48:11+00:00 hourly 0.9 https://trial.medpath.com/news/britain-s-drug-pricing-reckoning-raising-nice-s-cost-effectiveness-threshold-and-cutting-rebates-to-keep-gene-therapies-flowing 2026-08-12T15:47:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/britain-s-drug-pricing-reckoning-raising-nice-s-cost-effectiveness-threshold-and-cutting-rebates-to-keep-gene-therapies-flowing 2026-08-12T15:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/ai-framework-acscend-uncovers-hidden-cancer-stem-like-cell-states-linked-to-tumour-recurrence-and-immunotherapy-resistance 2026-08-12T14:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-framework-acscend-uncovers-hidden-cancer-stem-like-cell-states-linked-to-tumour-recurrence-and-immunotherapy-resistance 2026-08-12T14:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/tufts-csdd-analysis-finds-ai-clinical-monitoring-agents-can-deliver-up-to-21-million-in-net-financial-value-per-drug-program 2026-08-12T14:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tufts-csdd-analysis-finds-ai-clinical-monitoring-agents-can-deliver-up-to-21-million-in-net-financial-value-per-drug-program 2026-08-12T14:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/aprea-therapeutics-expands-global-patent-portfolio-for-wee1-and-atr-precision-oncology-programs 2026-08-12T14:47:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aprea-therapeutics-expands-global-patent-portfolio-for-wee1-and-atr-precision-oncology-programs 2026-08-12T14:47:54+00:00 hourly 0.9 https://trial.medpath.com/news/iterion-therapeutics-strengthens-board-as-tegavivint-expands-across-wnt-driven-cancers 2026-08-12T14:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterion-therapeutics-strengthens-board-as-tegavivint-expands-across-wnt-driven-cancers 2026-08-12T14:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/novel-hypercholesterolemia-drugs-market-to-reach-usd-42-8-billion-by-2036-as-oral-pcsk9-inhibition-and-gene-editing-expand-treatment-options 2026-08-12T14:47:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-hypercholesterolemia-drugs-market-to-reach-usd-42-8-billion-by-2036-as-oral-pcsk9-inhibition-and-gene-editing-expand-treatment-options 2026-08-12T14:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/cn-bio-awarded-ps180k-innovate-uk-grant-to-develop-human-relevant-alternative-to-animal-pharmacokinetic-studies 2026-08-12T12:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cn-bio-awarded-ps180k-innovate-uk-grant-to-develop-human-relevant-alternative-to-animal-pharmacokinetic-studies 2026-08-12T12:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/ochsner-health-and-paradigm-health-expand-clinical-trial-access-across-the-gulf-south-with-ai-native-recruitment-platform 2026-08-12T12:48:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ochsner-health-and-paradigm-health-expand-clinical-trial-access-across-the-gulf-south-with-ai-native-recruitment-platform 2026-08-12T12:48:27+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-publishes-defiance-study-results-plasma-dkk1-emerges-as-predictive-biomarker-for-sirexatamab-benefit-in-second-line-colorectal-cancer 2026-08-12T12:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-publishes-defiance-study-results-plasma-dkk1-emerges-as-predictive-biomarker-for-sirexatamab-benefit-in-second-line-colorectal-cancer 2026-08-12T12:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/again-acquires-genomatica-to-build-ai-driven-biomanufacturing-platform-spanning-discovery-to-industrial-scale 2026-08-12T11:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/again-acquires-genomatica-to-build-ai-driven-biomanufacturing-platform-spanning-discovery-to-industrial-scale 2026-08-12T11:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-s-vykat-xr-linked-to-patient-deaths-and-serious-adverse-events-in-prader-willi-syndrome 2026-08-12T11:48:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-s-vykat-xr-linked-to-patient-deaths-and-serious-adverse-events-in-prader-willi-syndrome 2026-08-12T11:48:47+00:00 hourly 0.9 https://trial.medpath.com/news/beyang-therapeutics-closes-oversubscribed-30-million-series-a-to-advance-ai-driven-drug-pipeline 2026-08-12T11:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyang-therapeutics-closes-oversubscribed-30-million-series-a-to-advance-ai-driven-drug-pipeline 2026-08-12T11:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/eloxx-pharmaceuticals-strengthens-balance-sheet-with-66-million-offering-advances-exaluren-toward-phase-2b-in-alport-syndrome 2026-08-12T11:47:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eloxx-pharmaceuticals-strengthens-balance-sheet-with-66-million-offering-advances-exaluren-toward-phase-2b-in-alport-syndrome 2026-08-12T11:47:57+00:00 hourly 0.9 https://trial.medpath.com/news/leap-therapeutics-reaches-fda-alignment-on-phase-3-trial-for-sirexatamab-in-dkk1-high-metastatic-colorectal-cancer 2026-08-12T11:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leap-therapeutics-reaches-fda-alignment-on-phase-3-trial-for-sirexatamab-in-dkk1-high-metastatic-colorectal-cancer 2026-08-12T11:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/south-korea-s-seven-major-seed-initiative-targets-brain-computer-interface-commercialization-and-ai-driven-drug-discovery-by-2035 2026-08-12T11:47:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/south-korea-s-seven-major-seed-initiative-targets-brain-computer-interface-commercialization-and-ai-driven-drug-discovery-by-2035 2026-08-12T11:47:42+00:00 hourly 0.9 https://trial.medpath.com/news/fact-check-no-evidence-covid-19-mrna-vaccines-raise-miscarriage-risk-82-figure-is-a-data-misrepresentation 2026-08-12T10:49:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fact-check-no-evidence-covid-19-mrna-vaccines-raise-miscarriage-risk-82-figure-is-a-data-misrepresentation 2026-08-12T10:49:35+00:00 hourly 0.9 https://trial.medpath.com/news/lilly-escalates-fight-against-illegal-retatrutide-black-market-with-six-new-lawsuits 2026-08-12T10:48:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lilly-escalates-fight-against-illegal-retatrutide-black-market-with-six-new-lawsuits 2026-08-12T10:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/expanded-access-case-report-shows-snipr001-an-engineered-crispr-phage-therapy-associated-with-89-reduction-in-multidrug-resistant-e-coli-malakoplakia-mass 2026-08-12T10:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expanded-access-case-report-shows-snipr001-an-engineered-crispr-phage-therapy-associated-with-89-reduction-in-multidrug-resistant-e-coli-malakoplakia-mass 2026-08-12T10:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/nih-awards-11-2-million-phase-2-grant-to-expand-university-of-arkansas-metabolic-research-center 2026-08-12T10:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nih-awards-11-2-million-phase-2-grant-to-expand-university-of-arkansas-metabolic-research-center 2026-08-12T10:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/l-oreal-and-nus-medicine-launch-joint-laboratory-to-decode-skin-as-a-window-into-healthy-longevity 2026-08-12T09:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/l-oreal-and-nus-medicine-launch-joint-laboratory-to-decode-skin-as-a-window-into-healthy-longevity 2026-08-12T09:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/childhood-trauma-leaves-a-lasting-epigenetic-scar-in-dopamine-neurons-via-setd7 2026-08-12T08:47:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/childhood-trauma-leaves-a-lasting-epigenetic-scar-in-dopamine-neurons-via-setd7 2026-08-12T08:47:18+00:00 hourly 0.9 https://trial.medpath.com/news/india-s-cdsco-mandates-ind-division-review-for-new-drugs-not-yet-approved-anywhere-globally 2026-08-12T05:47:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/india-s-cdsco-mandates-ind-division-review-for-new-drugs-not-yet-approved-anywhere-globally 2026-08-12T05:47:30+00:00 hourly 0.9 https://trial.medpath.com/news/blood-gene-signature-tied-to-cognitive-impairment-and-freezing-gait-in-parkinson-s-disease 2026-08-12T02:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-gene-signature-tied-to-cognitive-impairment-and-freezing-gait-in-parkinson-s-disease 2026-08-12T02:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-accepts-new-drug-application-for-laekna-s-akt-inhibitor-afuresertib-in-hr-her2-breast-cancer 2026-08-12T01:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-accepts-new-drug-application-for-laekna-s-akt-inhibitor-afuresertib-in-hr-her2-breast-cancer 2026-08-12T01:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-automates-slow-moving-inventory-management-with-sap-to-strengthen-global-supply-chain-resilience 2026-08-12T00:50:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-automates-slow-moving-inventory-management-with-sap-to-strengthen-global-supply-chain-resilience 2026-08-12T00:50:58+00:00 hourly 0.9 https://trial.medpath.com/news/bbot-advances-triple-kras-pi3ka-pipeline-with-dual-combination-dosing-reports-344m-cash-runway-into-2028 2026-08-11T22:00:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bbot-advances-triple-kras-pi3ka-pipeline-with-dual-combination-dosing-reports-344m-cash-runway-into-2028 2026-08-11T22:00:03+00:00 hourly 0.9 https://trial.medpath.com/news/leuko-2026-global-virtual-congress-unites-the-leukemia-community-on-advances-in-precision-medicine-and-cellular-therapy 2026-08-11T21:59:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/leuko-2026-global-virtual-congress-unites-the-leukemia-community-on-advances-in-precision-medicine-and-cellular-therapy 2026-08-11T21:59:58+00:00 hourly 0.9 https://trial.medpath.com/news/pliant-therapeutics-reports-strong-enrollment-in-fortify-trial-of-pln-101095-appoints-oncology-veterans-to-board 2026-08-11T21:58:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pliant-therapeutics-reports-strong-enrollment-in-fortify-trial-of-pln-101095-appoints-oncology-veterans-to-board 2026-08-11T21:58:00+00:00 hourly 0.9 https://trial.medpath.com/news/continuous-ocr-monitoring-detects-mitochondrial-cardiotoxicity-before-visible-cell-damage 2026-08-11T20:52:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/continuous-ocr-monitoring-detects-mitochondrial-cardiotoxicity-before-visible-cell-damage 2026-08-11T20:52:13+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-researchers-uncover-immune-memory-drivers-of-recurrent-arthritis-after-checkpoint-inhibitor-therapy 2026-08-11T20:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-researchers-uncover-immune-memory-drivers-of-recurrent-arthritis-after-checkpoint-inhibitor-therapy 2026-08-11T20:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/omega-3-fatty-acids-could-unlock-a-new-nanomedicine-approach-for-treating-ards 2026-08-11T19:50:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/omega-3-fatty-acids-could-unlock-a-new-nanomedicine-approach-for-treating-ards 2026-08-11T19:50:21+00:00 hourly 0.9 https://trial.medpath.com/news/researchers-uncover-cd44-epha2-endosomal-pathway-that-could-unlock-antisense-therapy-for-cancer 2026-08-11T19:50:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/researchers-uncover-cd44-epha2-endosomal-pathway-that-could-unlock-antisense-therapy-for-cancer 2026-08-11T19:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/social-security-adds-14-conditions-to-compassionate-allowances-list-expanding-fast-track-disability-benefits 2026-08-11T19:50:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/social-security-adds-14-conditions-to-compassionate-allowances-list-expanding-fast-track-disability-benefits 2026-08-11T19:50:12+00:00 hourly 0.9 https://trial.medpath.com/news/cmi-media-group-launches-rare-disease-center-of-excellence-to-bridge-precision-marketing-gap-for-orphan-therapies 2026-08-11T18:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cmi-media-group-launches-rare-disease-center-of-excellence-to-bridge-precision-marketing-gap-for-orphan-therapies 2026-08-11T18:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/gibson-oncology-s-lmp744-advances-to-phase-ii-first-patient-completes-initial-treatment-cycle-in-recurrent-glioblastoma-trial 2026-08-11T18:47:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gibson-oncology-s-lmp744-advances-to-phase-ii-first-patient-completes-initial-treatment-cycle-in-recurrent-glioblastoma-trial 2026-08-11T18:47:37+00:00 hourly 0.9 https://trial.medpath.com/news/uh-college-of-pharmacy-secures-over-1-million-for-sepsis-nanomedicine-ai-driven-dementia-research-and-sickle-cell-depression-screening 2026-08-11T18:47:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uh-college-of-pharmacy-secures-over-1-million-for-sepsis-nanomedicine-ai-driven-dementia-research-and-sickle-cell-depression-screening 2026-08-11T18:47:28+00:00 hourly 0.9 https://trial.medpath.com/news/uncoverseq-sets-new-benchmark-for-crispr-off-target-detection-with-97-6-sensitivity 2026-08-11T17:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uncoverseq-sets-new-benchmark-for-crispr-off-target-detection-with-97-6-sensitivity 2026-08-11T17:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/artelo-biosciences-receives-u-s-patent-notice-of-allowance-for-art27-13-commercial-formulation 2026-08-11T16:52:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/artelo-biosciences-receives-u-s-patent-notice-of-allowance-for-art27-13-commercial-formulation 2026-08-11T16:52:39+00:00 hourly 0.9 https://trial.medpath.com/news/mngs-identifies-acute-q-fever-presenting-as-sepsis-with-multisystem-involvement-in-an-immunosuppressed-patient 2026-08-11T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mngs-identifies-acute-q-fever-presenting-as-sepsis-with-multisystem-involvement-in-an-immunosuppressed-patient 2026-08-11T16:51:58+00:00 hourly 0.9 https://trial.medpath.com/news/integrated-care-models-bridge-gaps-in-treating-opioid-use-disorder-and-chronic-pain 2026-08-11T16:51:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/integrated-care-models-bridge-gaps-in-treating-opioid-use-disorder-and-chronic-pain 2026-08-11T16:51:33+00:00 hourly 0.9 https://trial.medpath.com/news/belenos-bispecific-antibody-bel512-hits-all-endpoints-in-phase-2-crswnp-trial-secures-breakthrough-therapy-designation-in-china 2026-08-11T16:51:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/belenos-bispecific-antibody-bel512-hits-all-endpoints-in-phase-2-crswnp-trial-secures-breakthrough-therapy-designation-in-china 2026-08-11T16:51:10+00:00 hourly 0.9 https://trial.medpath.com/news/alfasigma-to-acquire-nordic-group-b-v-expanding-specialty-care-portfolio-and-european-presence 2026-08-11T16:50:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alfasigma-to-acquire-nordic-group-b-v-expanding-specialty-care-portfolio-and-european-presence 2026-08-11T16:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-and-nucleai-expand-ai-powered-tissue-intelligence-collaboration-for-adc-biomarker-discovery 2026-08-11T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-and-nucleai-expand-ai-powered-tissue-intelligence-collaboration-for-adc-biomarker-discovery 2026-08-11T16:49:34+00:00 hourly 0.9 https://trial.medpath.com/news/ani-pharmaceuticals-posts-record-q2-2026-revenue-as-cortrophin-gel-expansion-drives-rare-disease-growth 2026-08-11T16:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ani-pharmaceuticals-posts-record-q2-2026-revenue-as-cortrophin-gel-expansion-drives-rare-disease-growth 2026-08-11T16:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/neighborhood-social-vulnerability-linked-to-worse-ovarian-cancer-survival-with-disproportionate-impact-on-black-women 2026-08-11T16:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neighborhood-social-vulnerability-linked-to-worse-ovarian-cancer-survival-with-disproportionate-impact-on-black-women 2026-08-11T16:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/infinimmune-raises-75m-series-a-to-advance-il-22-and-il-13-antibodies-for-atopic-dermatitis-toward-2027-clinical-entry 2026-08-11T16:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/infinimmune-raises-75m-series-a-to-advance-il-22-and-il-13-antibodies-for-atopic-dermatitis-toward-2027-clinical-entry 2026-08-11T16:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/soter-bio-ends-lobbying-relationship-with-tenagrity-solutions-after-18-months 2026-08-11T16:48:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/soter-bio-ends-lobbying-relationship-with-tenagrity-solutions-after-18-months 2026-08-11T16:48:20+00:00 hourly 0.9 https://trial.medpath.com/news/graviton-bioscience-secures-fda-ind-clearance-for-gv101-a-novel-rock2-inhibitor-for-friedreich-s-ataxia 2026-08-11T15:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/graviton-bioscience-secures-fda-ind-clearance-for-gv101-a-novel-rock2-inhibitor-for-friedreich-s-ataxia 2026-08-11T15:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/ex-legend-ceo-ying-huang-takes-helm-at-k2-therapeutics-as-startup-secures-50m-seed-financing 2026-08-11T15:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ex-legend-ceo-ying-huang-takes-helm-at-k2-therapeutics-as-startup-secures-50m-seed-financing 2026-08-11T15:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/otraces-claims-its-proteomic-method-can-predict-stage-3-type-1-diabetes-up-to-five-years-before-onset 2026-08-11T15:47:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/otraces-claims-its-proteomic-method-can-predict-stage-3-type-1-diabetes-up-to-five-years-before-onset 2026-08-11T15:47:27+00:00 hourly 0.9 https://trial.medpath.com/news/amneal-completes-kashiv-acquisition-building-an-integrated-global-biosimilars-platform 2026-08-11T14:49:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amneal-completes-kashiv-acquisition-building-an-integrated-global-biosimilars-platform 2026-08-11T14:49:59+00:00 hourly 0.9 https://trial.medpath.com/news/pharmd-summer-research-fellows-study-real-world-safety-of-a-novel-schizophrenia-treatment 2026-08-11T14:49:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmd-summer-research-fellows-study-real-world-safety-of-a-novel-schizophrenia-treatment 2026-08-11T14:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-aatd-ld 2026-08-11T14:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sentynl-therapeutics-and-mereo-biopharma-announce-option-and-license-agreement-for-alvelestat-in-aatd-ld 2026-08-11T14:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/xprize-names-20-finalist-teams-in-101m-healthspan-competition-to-reverse-biological-aging 2026-08-11T14:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xprize-names-20-finalist-teams-in-101m-healthspan-competition-to-reverse-biological-aging 2026-08-11T14:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-previously-unknown-ability-of-the-adult-brain-to-repair-itself-via-regenerative-astrocytes 2026-08-11T14:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-previously-unknown-ability-of-the-adult-brain-to-repair-itself-via-regenerative-astrocytes 2026-08-11T14:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/metabolon-launches-peak-science-grant-program-to-accelerate-metabolomics-driven-discovery 2026-08-11T14:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metabolon-launches-peak-science-grant-program-to-accelerate-metabolomics-driven-discovery 2026-08-11T14:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/shared-lysosomal-pathway-drives-neurodegeneration-in-rare-childhood-dementia-and-alzheimer-s-uc-san-diego-study-reveals 2026-08-11T14:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shared-lysosomal-pathway-drives-neurodegeneration-in-rare-childhood-dementia-and-alzheimer-s-uc-san-diego-study-reveals 2026-08-11T14:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/fastwave-medical-gains-fda-ide-approval-to-begin-pivotal-trial-of-artero-peripheral-ivl-system 2026-08-11T13:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fastwave-medical-gains-fda-ide-approval-to-begin-pivotal-trial-of-artero-peripheral-ivl-system 2026-08-11T13:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/moody-s-upgrades-teva-to-investment-grade-marking-milestone-in-pivot-to-growth-strategy 2026-08-11T13:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moody-s-upgrades-teva-to-investment-grade-marking-milestone-in-pivot-to-growth-strategy 2026-08-11T13:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/greek-court-upholds-novartis-entresto-spc-defining-product-by-active-ingredients-not-solid-state-form 2026-08-11T13:47:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greek-court-upholds-novartis-entresto-spc-defining-product-by-active-ingredients-not-solid-state-form 2026-08-11T13:47:36+00:00 hourly 0.9 https://trial.medpath.com/news/unmc-college-of-medicine-hosts-fourth-annual-medical-student-research-showcase 2026-08-11T12:48:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unmc-college-of-medicine-hosts-fourth-annual-medical-student-research-showcase 2026-08-11T12:48:09+00:00 hourly 0.9 https://trial.medpath.com/news/russia-begins-bioequivalence-trials-of-generic-gilteritinib-for-flt3-mutated-acute-myeloid-leukaemia 2026-08-11T12:48:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/russia-begins-bioequivalence-trials-of-generic-gilteritinib-for-flt3-mutated-acute-myeloid-leukaemia 2026-08-11T12:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/oncofertility-expands-as-younger-cancer-patients-turn-to-new-fertility-preservation-technologies 2026-08-11T12:47:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oncofertility-expands-as-younger-cancer-patients-turn-to-new-fertility-preservation-technologies 2026-08-11T12:47:59+00:00 hourly 0.9 https://trial.medpath.com/news/vaderis-therapeutics-secures-152m-series-b-launches-phase-3-heroic-trial-of-engasertib-for-hht 2026-08-11T12:47:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vaderis-therapeutics-secures-152m-series-b-launches-phase-3-heroic-trial-of-engasertib-for-hht 2026-08-11T12:47:37+00:00 hourly 0.9 https://trial.medpath.com/news/simple-fitness-tests-predict-all-cause-mortality-in-older-adults-study-finds 2026-08-11T12:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simple-fitness-tests-predict-all-cause-mortality-in-older-adults-study-finds 2026-08-11T12:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/alzai-and-linus-health-forge-ai-driven-collaboration-for-early-alzheimer-s-risk-detection 2026-08-11T11:59:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzai-and-linus-health-forge-ai-driven-collaboration-for-early-alzheimer-s-risk-detection 2026-08-11T11:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/blood-immune-cell-changes-may-predict-melanoma-immunotherapy-outcomes 2026-08-11T10:20:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-immune-cell-changes-may-predict-melanoma-immunotherapy-outcomes 2026-08-11T10:20:51+00:00 hourly 0.9 https://trial.medpath.com/news/verici-dx-achieves-olink-certified-service-provider-status-expanding-proteomics-capabilities-for-transplant-diagnostics 2026-08-11T10:20:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verici-dx-achieves-olink-certified-service-provider-status-expanding-proteomics-capabilities-for-transplant-diagnostics 2026-08-11T10:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/huons-global-bets-on-china-hutox-exports-to-revive-earnings-as-korean-toxin-makers-expand-overseas 2026-08-11T10:18:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/huons-global-bets-on-china-hutox-exports-to-revive-earnings-as-korean-toxin-makers-expand-overseas 2026-08-11T10:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/obinutuzumab-beta-posts-93-1-relapse-reduction-in-aqp4-nmosd-joining-a-crowded-efficacy-plateau 2026-08-11T10:18:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obinutuzumab-beta-posts-93-1-relapse-reduction-in-aqp4-nmosd-joining-a-crowded-efficacy-plateau 2026-08-11T10:18:03+00:00 hourly 0.9 https://trial.medpath.com/news/pakistan-s-hiv-surge-exposes-systemic-infection-control-failures-in-healthcare-facilities 2026-08-11T10:16:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pakistan-s-hiv-surge-exposes-systemic-infection-control-failures-in-healthcare-facilities 2026-08-11T10:16:32+00:00 hourly 0.9 https://trial.medpath.com/news/h-r-1-medicaid-cuts-threaten-hospital-finances-as-uninsured-rate-climbs-toward-16-million-more-americans 2026-08-11T10:07:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/h-r-1-medicaid-cuts-threaten-hospital-finances-as-uninsured-rate-climbs-toward-16-million-more-americans 2026-08-11T10:07:35+00:00 hourly 0.9 https://trial.medpath.com/news/acog-releases-2026-27-respiratory-virus-immunization-guidance-extending-rsv-vaccination-window-for-pregnant-individuals 2026-08-11T10:07:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/acog-releases-2026-27-respiratory-virus-immunization-guidance-extending-rsv-vaccination-window-for-pregnant-individuals 2026-08-11T10:07:07+00:00 hourly 0.9 https://trial.medpath.com/news/fauci-texts-reveal-early-concerns-about-mrna-vaccine-second-dose-reactions-and-theoretical-miscarriage-risk-in-pregnant-women 2026-08-11T10:06:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fauci-texts-reveal-early-concerns-about-mrna-vaccine-second-dose-reactions-and-theoretical-miscarriage-risk-in-pregnant-women 2026-08-11T10:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/schizophrenia-s-synaptic-loss-follows-the-brain-s-molecular-and-connectivity-architecture-pet-study-finds 2026-08-10T19:24:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/schizophrenia-s-synaptic-loss-follows-the-brain-s-molecular-and-connectivity-architecture-pet-study-finds 2026-08-10T19:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/genomic-newborn-screening-catches-rare-diseases-before-symptoms-start-with-early-trials-flagging-treatable-conditions-in-up-to-4-of-infants 2026-08-10T18:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genomic-newborn-screening-catches-rare-diseases-before-symptoms-start-with-early-trials-flagging-treatable-conditions-in-up-to-4-of-infants 2026-08-10T18:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/ex-biontech-execs-launch-ai-native-cancer-surveillance-company-bios-life-with-25m-and-tempus-partnership 2026-08-10T17:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ex-biontech-execs-launch-ai-native-cancer-surveillance-company-bios-life-with-25m-and-tempus-partnership 2026-08-10T17:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/us-sees-sharp-rise-in-cannabis-hyperemesis-syndrome-emergency-visits-after-new-diagnosis-code 2026-08-10T17:49:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-sees-sharp-rise-in-cannabis-hyperemesis-syndrome-emergency-visits-after-new-diagnosis-code 2026-08-10T17:49:07+00:00 hourly 0.9 https://trial.medpath.com/news/largest-real-world-study-finds-early-oseltamivir-treatment-reduces-icu-admissions-in-hospitalized-children-with-influenza 2026-08-10T17:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/largest-real-world-study-finds-early-oseltamivir-treatment-reduces-icu-admissions-in-hospitalized-children-with-influenza 2026-08-10T17:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/mabwell-clears-brazilian-anvisa-gmp-inspection-for-denosumab-biosimilars-paving-way-for-latin-american-market-access 2026-08-10T16:49:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mabwell-clears-brazilian-anvisa-gmp-inspection-for-denosumab-biosimilars-paving-way-for-latin-american-market-access 2026-08-10T16:49:22+00:00 hourly 0.9 https://trial.medpath.com/news/kazakhstan-registers-promomed-s-tirzetta-as-first-officially-available-tirzepatide-drug-in-the-country 2026-08-10T16:49:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kazakhstan-registers-promomed-s-tirzetta-as-first-officially-available-tirzepatide-drug-in-the-country 2026-08-10T16:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/bristol-myers-squibb-selects-houston-for-2-3-billion-multi-modal-manufacturing-campus 2026-08-10T16:48:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bristol-myers-squibb-selects-houston-for-2-3-billion-multi-modal-manufacturing-campus 2026-08-10T16:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/fc-fusion-therapeutics-market-poised-to-reach-53-5-billion-by-2035-as-oncology-pipeline-expands 2026-08-10T16:48:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fc-fusion-therapeutics-market-poised-to-reach-53-5-billion-by-2035-as-oncology-pipeline-expands 2026-08-10T16:48:37+00:00 hourly 0.9 https://trial.medpath.com/news/vcu-massey-comprehensive-cancer-center-awarded-2-7-million-nih-k12-grant-to-train-next-generation-of-community-oncology-researchers 2026-08-10T16:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vcu-massey-comprehensive-cancer-center-awarded-2-7-million-nih-k12-grant-to-train-next-generation-of-community-oncology-researchers 2026-08-10T16:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/hhs-proposes-mandatory-gras-notification-rule-marking-first-major-fda-food-ingredient-transparency-reform-in-decades 2026-08-10T16:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hhs-proposes-mandatory-gras-notification-rule-marking-first-major-fda-food-ingredient-transparency-reform-in-decades 2026-08-10T16:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/capricor-therapeutics-to-report-second-quarter-2026-financial-results-and-corporate-update-on-august-13 2026-08-10T15:50:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/capricor-therapeutics-to-report-second-quarter-2026-financial-results-and-corporate-update-on-august-13 2026-08-10T15:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-wins-u-s-fda-clearance-for-clinical-trials-of-novel-mpox-mrna-vaccine-sys6037 2026-08-10T15:49:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-wins-u-s-fda-clearance-for-clinical-trials-of-novel-mpox-mrna-vaccine-sys6037 2026-08-10T15:49:04+00:00 hourly 0.9 https://trial.medpath.com/news/chrissy-metz-turns-to-glp-1-therapy-through-telehealth-platform-ro-after-years-of-skepticism 2026-08-10T15:48:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chrissy-metz-turns-to-glp-1-therapy-through-telehealth-platform-ro-after-years-of-skepticism 2026-08-10T15:48:50+00:00 hourly 0.9 https://trial.medpath.com/news/immunitybio-appoints-former-world-bank-president-dr-jim-yong-kim-as-vice-chairman-to-drive-global-access-initiatives 2026-08-10T15:47:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunitybio-appoints-former-world-bank-president-dr-jim-yong-kim-as-vice-chairman-to-drive-global-access-initiatives 2026-08-10T15:47:42+00:00 hourly 0.9 https://trial.medpath.com/news/telomir-zn-suppresses-tumor-growth-in-tnbc-and-prostate-cancer-models-via-iron-dependent-kdm-inhibition-preclinical-study-shows 2026-08-10T14:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/telomir-zn-suppresses-tumor-growth-in-tnbc-and-prostate-cancer-models-via-iron-dependent-kdm-inhibition-preclinical-study-shows 2026-08-10T14:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/remedium-bio-secures-10-million-series-a-led-by-lifespan-vision-ventures-with-lilly-participation-to-advance-adjustable-gene-therapy-platform 2026-08-10T14:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/remedium-bio-secures-10-million-series-a-led-by-lifespan-vision-ventures-with-lilly-participation-to-advance-adjustable-gene-therapy-platform 2026-08-10T14:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/higher-cumulative-doses-of-clomiphene-citrate-linked-to-increased-miscarriage-risk-without-improving-live-birth-odds 2026-08-10T13:49:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/higher-cumulative-doses-of-clomiphene-citrate-linked-to-increased-miscarriage-risk-without-improving-live-birth-odds 2026-08-10T13:49:31+00:00 hourly 0.9 https://trial.medpath.com/news/eikon-therapeutics-appoints-cp-chang-as-chief-scientific-officer-to-advance-oncology-pipeline 2026-08-10T13:48:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eikon-therapeutics-appoints-cp-chang-as-chief-scientific-officer-to-advance-oncology-pipeline 2026-08-10T13:48:33+00:00 hourly 0.9 https://trial.medpath.com/news/clene-presents-nfl-biomarker-data-for-cnm-au8-in-als-plans-nda-filing-for-accelerated-approval 2026-08-10T13:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clene-presents-nfl-biomarker-data-for-cnm-au8-in-als-plans-nda-filing-for-accelerated-approval 2026-08-10T13:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/jazz-pharmaceuticals-to-acquire-actio-biosciences-for-820-million-securing-first-in-class-kcnt1-epilepsy-therapy-abs-1230 2026-08-10T12:47:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jazz-pharmaceuticals-to-acquire-actio-biosciences-for-820-million-securing-first-in-class-kcnt1-epilepsy-therapy-abs-1230 2026-08-10T12:47:34+00:00 hourly 0.9 https://trial.medpath.com/news/olix-pharmaceuticals-files-u-s-patent-for-circular-mrna-manufacturing-platform 2026-08-10T11:48:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/olix-pharmaceuticals-files-u-s-patent-for-circular-mrna-manufacturing-platform 2026-08-10T11:48:56+00:00 hourly 0.9 https://trial.medpath.com/news/bruker-makes-majority-investment-in-mimetas-to-expand-human-relevant-drug-discovery-platform 2026-08-10T11:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bruker-makes-majority-investment-in-mimetas-to-expand-human-relevant-drug-discovery-platform 2026-08-10T11:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/beone-medicines-and-revolution-medicines-forge-multi-part-collaboration-to-advance-ras-on-inhibitors-for-ras-addicted-cancers 2026-08-10T11:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beone-medicines-and-revolution-medicines-forge-multi-part-collaboration-to-advance-ras-on-inhibitors-for-ras-addicted-cancers 2026-08-10T11:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/labcorp-s-pgdx-elio-tissue-complete-cdx-gains-fda-approval-as-companion-diagnostic-for-braf-mutant-advanced-melanoma 2026-08-10T11:48:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/labcorp-s-pgdx-elio-tissue-complete-cdx-gains-fda-approval-as-companion-diagnostic-for-braf-mutant-advanced-melanoma 2026-08-10T11:48:12+00:00 hourly 0.9 https://trial.medpath.com/news/weekly-cladribine-plus-rituximab-shows-promise-against-hairy-cell-leukemia 2026-08-10T11:48:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/weekly-cladribine-plus-rituximab-shows-promise-against-hairy-cell-leukemia 2026-08-10T11:48:08+00:00 hourly 0.9 https://trial.medpath.com/news/digital-science-launches-dimensions-mcp-servers-to-bridge-enterprise-ai-agents-with-live-research-intelligence 2026-08-10T11:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/digital-science-launches-dimensions-mcp-servers-to-bridge-enterprise-ai-agents-with-live-research-intelligence 2026-08-10T11:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-radiation-the-research-seeking-a-future-for-children-with-dipg 2026-08-10T11:47:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-radiation-the-research-seeking-a-future-for-children-with-dipg 2026-08-10T11:47:49+00:00 hourly 0.9 https://trial.medpath.com/news/novonesis-to-acquire-remaining-stake-in-microbiogen-strengthening-industrial-yeast-platform 2026-08-10T11:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novonesis-to-acquire-remaining-stake-in-microbiogen-strengthening-industrial-yeast-platform 2026-08-10T11:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/immunocine-cancer-center-appoints-johns-hopkins-veteran-dr-stephen-j-noga-as-chief-medical-officer-to-advance-personalized-dendritic-cell-immunotherapy 2026-08-10T10:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunocine-cancer-center-appoints-johns-hopkins-veteran-dr-stephen-j-noga-as-chief-medical-officer-to-advance-personalized-dendritic-cell-immunotherapy 2026-08-10T10:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/triple-dose-regimen-may-permanently-clear-hiv-in-newborns-primate-study-shows 2026-08-10T10:47:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/triple-dose-regimen-may-permanently-clear-hiv-in-newborns-primate-study-shows 2026-08-10T10:47:40+00:00 hourly 0.9 https://trial.medpath.com/news/chinese-researchers-use-microbubbles-and-ultrasound-to-shrink-aggressive-liver-tumours 2026-08-10T10:47:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chinese-researchers-use-microbubbles-and-ultrasound-to-shrink-aggressive-liver-tumours 2026-08-10T10:47:36+00:00 hourly 0.9 https://trial.medpath.com/news/thermo-fisher-doubles-down-on-india-targeting-15-20-customer-growth-as-biopharma-shifts-to-biologics 2026-08-10T10:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/thermo-fisher-doubles-down-on-india-targeting-15-20-customer-growth-as-biopharma-shifts-to-biologics 2026-08-10T10:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/liposomal-bupivacaine-blocks-cut-opioid-use-and-speed-recovery-in-elderly-laparoscopic-hernia-repair 2026-08-10T09:48:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liposomal-bupivacaine-blocks-cut-opioid-use-and-speed-recovery-in-elderly-laparoscopic-hernia-repair 2026-08-10T09:48:18+00:00 hourly 0.9 https://trial.medpath.com/news/heron-therapeutics-resets-balance-sheet-and-withdraws-2026-guidance-after-cinvanti-patent-ruling 2026-08-10T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heron-therapeutics-resets-balance-sheet-and-withdraws-2026-guidance-after-cinvanti-patent-ruling 2026-08-10T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/almirall-partners-with-crystalo-to-develop-ai-driven-ion-channel-small-molecules-for-dermatology 2026-08-10T07:49:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/almirall-partners-with-crystalo-to-develop-ai-driven-ion-channel-small-molecules-for-dermatology 2026-08-10T07:49:19+00:00 hourly 0.9 https://trial.medpath.com/news/biotech-funds-lead-global-equity-performance-as-healthcare-outpaces-tech-during-summer-volatility 2026-08-10T07:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biotech-funds-lead-global-equity-performance-as-healthcare-outpaces-tech-during-summer-volatility 2026-08-10T07:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/sobi-and-innate-pharma-enter-strategic-partnership-to-advance-lacutamab-toward-accelerated-approval-in-sezary-syndrome 2026-08-10T06:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sobi-and-innate-pharma-enter-strategic-partnership-to-advance-lacutamab-toward-accelerated-approval-in-sezary-syndrome 2026-08-10T06:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/biophytis-secures-anvisa-approval-for-phase-2-oba-trial-of-bio101-in-obesity-expanding-multi-regional-development 2026-08-10T05:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biophytis-secures-anvisa-approval-for-phase-2-oba-trial-of-bio101-in-obesity-expanding-multi-regional-development 2026-08-10T05:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/vietnam-and-australia-partner-to-develop-mrna-vaccines-for-influenza-and-personalized-cancer-vaccines 2026-08-10T05:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vietnam-and-australia-partner-to-develop-mrna-vaccines-for-influenza-and-personalized-cancer-vaccines 2026-08-10T05:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/genfleet-s-oral-kras-g12d-inhibitor-gfh375-enters-registrational-phase-iii-trial-in-nsclc-first-of-its-kind-globally 2026-08-10T03:47:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genfleet-s-oral-kras-g12d-inhibitor-gfh375-enters-registrational-phase-iii-trial-in-nsclc-first-of-its-kind-globally 2026-08-10T03:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/hetao-zone-poised-to-accelerate-hong-kong-s-medical-r-d-ambitions-through-cross-border-clinical-trials 2026-08-10T01:48:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hetao-zone-poised-to-accelerate-hong-kong-s-medical-r-d-ambitions-through-cross-border-clinical-trials 2026-08-10T01:48:11+00:00 hourly 0.9 https://trial.medpath.com/news/rising-drug-prices-and-shortages-force-iranian-cancer-patients-to-delay-or-abandon-treatment 2026-08-10T01:48:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rising-drug-prices-and-shortages-force-iranian-cancer-patients-to-delay-or-abandon-treatment 2026-08-10T01:48:07+00:00 hourly 0.9 https://trial.medpath.com/news/milliman-becomes-second-private-company-in-japan-to-earn-certified-pseudonymized-medical-information-user-status 2026-08-10T01:48:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/milliman-becomes-second-private-company-in-japan-to-earn-certified-pseudonymized-medical-information-user-status 2026-08-10T01:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/kyungdong-pharmaceutical-and-asimov-complete-ai-driven-cell-line-development-for-next-generation-biosimilar-antibody 2026-08-10T00:47:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kyungdong-pharmaceutical-and-asimov-complete-ai-driven-cell-line-development-for-next-generation-biosimilar-antibody 2026-08-10T00:47:28+00:00 hourly 0.9 https://trial.medpath.com/news/quantum-enhanced-graph-neural-network-boosts-hiv-and-alzheimer-s-drug-screening-accuracy 2026-08-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quantum-enhanced-graph-neural-network-boosts-hiv-and-alzheimer-s-drug-screening-accuracy 2026-08-10T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nus-researchers-achieve-multiplexed-optogenetic-control-of-yeast-using-red-and-blue-light 2026-08-09T22:52:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nus-researchers-achieve-multiplexed-optogenetic-control-of-yeast-using-red-and-blue-light 2026-08-09T22:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/wvu-medicine-princeton-community-hospital-earns-national-recognition-for-high-performing-knee-replacement-and-top-5-clinical-outcomes 2026-08-09T22:52:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wvu-medicine-princeton-community-hospital-earns-national-recognition-for-high-performing-knee-replacement-and-top-5-clinical-outcomes 2026-08-09T22:52:13+00:00 hourly 0.9 https://trial.medpath.com/news/people-with-eczema-face-28-higher-risk-of-developing-shingles-large-uk-database-study-finds 2026-08-09T21:48:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/people-with-eczema-face-28-higher-risk-of-developing-shingles-large-uk-database-study-finds 2026-08-09T21:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/us-fda-regulatory-risk-remains-a-defining-challenge-for-indian-pharma-stocks 2026-08-09T21:48:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-fda-regulatory-risk-remains-a-defining-challenge-for-indian-pharma-stocks 2026-08-09T21:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/georgia-woman-alleges-unneeded-hysterectomy-followed-cancer-misdiagnosis-from-pathology-labeling-error 2026-08-09T19:48:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/georgia-woman-alleges-unneeded-hysterectomy-followed-cancer-misdiagnosis-from-pathology-labeling-error 2026-08-09T19:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/iran-unveils-first-domestic-oncolytic-virus-platform-launches-clinical-trial-for-hard-to-treat-cancers 2026-08-09T18:47:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iran-unveils-first-domestic-oncolytic-virus-platform-launches-clinical-trial-for-hard-to-treat-cancers 2026-08-09T18:47:58+00:00 hourly 0.9 https://trial.medpath.com/news/grand-pharma-s-fap-targeted-radiopharmaceutical-gpn01530-2-earns-fda-fast-track-designation-for-solid-tumor-diagnosis 2026-08-09T17:48:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/grand-pharma-s-fap-targeted-radiopharmaceutical-gpn01530-2-earns-fda-fast-track-designation-for-solid-tumor-diagnosis 2026-08-09T17:48:50+00:00 hourly 0.9 https://trial.medpath.com/news/fda-and-usp-independently-agree-a-single-hplc-result-is-not-enough-to-confirm-peptide-identity 2026-08-09T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-and-usp-independently-agree-a-single-hplc-result-is-not-enough-to-confirm-peptide-identity 2026-08-09T16:48:39+00:00 hourly 0.9 https://trial.medpath.com/news/rowan-university-researchers-use-3d-bioprinting-to-build-living-chondrosarcoma-models-for-studying-bone-cancer-invasion 2026-08-09T16:48:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rowan-university-researchers-use-3d-bioprinting-to-build-living-chondrosarcoma-models-for-studying-bone-cancer-invasion 2026-08-09T16:48:29+00:00 hourly 0.9 https://trial.medpath.com/news/social-media-misinformation-and-policy-shifts-reshape-contraception-landscape-amid-rising-abortion-rates 2026-08-09T16:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/social-media-misinformation-and-policy-shifts-reshape-contraception-landscape-amid-rising-abortion-rates 2026-08-09T16:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/oak-park-fire-department-joins-30-year-illinois-study-tracking-cancer-risk-through-biomarker-monitoring 2026-08-09T16:48:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oak-park-fire-department-joins-30-year-illinois-study-tracking-cancer-risk-through-biomarker-monitoring 2026-08-09T16:48:12+00:00 hourly 0.9 https://trial.medpath.com/news/brazilian-club-coritiba-honors-english-fan-with-mnd-through-shirt-tribute-and-awareness-campaign 2026-08-09T15:48:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brazilian-club-coritiba-honors-english-fan-with-mnd-through-shirt-tribute-and-awareness-campaign 2026-08-09T15:48:31+00:00 hourly 0.9 https://trial.medpath.com/news/teva-seeks-to-bar-references-to-israeli-identity-in-generic-drug-price-fixing-trial-citing-gaza-war-prejudice 2026-08-09T14:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/teva-seeks-to-bar-references-to-israeli-identity-in-generic-drug-price-fixing-trial-citing-gaza-war-prejudice 2026-08-09T14:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/type-2-diabetes-accelerates-clinical-progression-of-aortic-stenosis-nationwide-swedish-study-finds 2026-08-09T13:48:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/type-2-diabetes-accelerates-clinical-progression-of-aortic-stenosis-nationwide-swedish-study-finds 2026-08-09T13:48:05+00:00 hourly 0.9 https://trial.medpath.com/news/liquidia-s-yutrepia-receives-fda-fast-track-designation-for-systemic-sclerosis-associated-raynaud-s-phenomenon 2026-08-09T13:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/liquidia-s-yutrepia-receives-fda-fast-track-designation-for-systemic-sclerosis-associated-raynaud-s-phenomenon 2026-08-09T13:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/montage-health-launches-1-56m-peer-led-youth-opioid-and-substance-use-prevention-program-in-monterey-county 2026-08-09T12:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/montage-health-launches-1-56m-peer-led-youth-opioid-and-substance-use-prevention-program-in-monterey-county 2026-08-09T12:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/jordan-enacts-updated-biosimilar-drug-registration-instructions-of-2026 2026-08-09T12:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jordan-enacts-updated-biosimilar-drug-registration-instructions-of-2026 2026-08-09T12:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/ps2-5m-cancer-research-uk-grant-to-advance-ovarian-cancer-drug-discovery-at-university-of-manchester 2026-08-09T11:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ps2-5m-cancer-research-uk-grant-to-advance-ovarian-cancer-drug-discovery-at-university-of-manchester 2026-08-09T11:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/ionis-pharmaceuticals-faces-securities-fraud-investigation-after-phase-3-cardio-ttransform-trial-failure-sends-shares-down-23 2026-08-09T09:47:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ionis-pharmaceuticals-faces-securities-fraud-investigation-after-phase-3-cardio-ttransform-trial-failure-sends-shares-down-23 2026-08-09T09:47:37+00:00 hourly 0.9 https://trial.medpath.com/news/dengue-season-shifts-earlier-in-india-as-clinicians-push-back-on-papaya-leaf-juice-and-coconut-water-as-cures 2026-08-09T08:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dengue-season-shifts-earlier-in-india-as-clinicians-push-back-on-papaya-leaf-juice-and-coconut-water-as-cures 2026-08-09T08:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/multiple-sclerosis-drug-markets-in-iceland-and-germany-divergent-dynamics-driven-by-prevalence-and-healthcare-systems 2026-08-09T02:48:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/multiple-sclerosis-drug-markets-in-iceland-and-germany-divergent-dynamics-driven-by-prevalence-and-healthcare-systems 2026-08-09T02:48:06+00:00 hourly 0.9 https://trial.medpath.com/news/celldex-therapeutics-signals-mixed-outlook-with-latest-pipeline-update 2026-08-08T23:47:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celldex-therapeutics-signals-mixed-outlook-with-latest-pipeline-update 2026-08-08T23:47:46+00:00 hourly 0.9 https://trial.medpath.com/news/hunter-biden-reveals-former-president-joe-biden-s-prostate-cancer-has-metastasized-to-bones 2026-08-08T19:47:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hunter-biden-reveals-former-president-joe-biden-s-prostate-cancer-has-metastasized-to-bones 2026-08-08T19:47:53+00:00 hourly 0.9 https://trial.medpath.com/news/eyepoint-pharmaceuticals-advances-durability-focused-phase-3-trial-design-for-retinal-disease 2026-08-08T19:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eyepoint-pharmaceuticals-advances-durability-focused-phase-3-trial-design-for-retinal-disease 2026-08-08T19:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/doximity-s-clinical-ai-assistant-tops-noharm-safety-benchmark-as-ai-adoption-surges-across-healthcare-workflows 2026-08-08T18:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doximity-s-clinical-ai-assistant-tops-noharm-safety-benchmark-as-ai-adoption-surges-across-healthcare-workflows 2026-08-08T18:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/insight-platform-maps-in-vivo-signaling-networks-of-disseminated-glioblastoma-cells-revealing-new-therapeutic-vulnerabilities 2026-08-08T17:49:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insight-platform-maps-in-vivo-signaling-networks-of-disseminated-glioblastoma-cells-revealing-new-therapeutic-vulnerabilities 2026-08-08T17:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/royan-institute-and-university-of-duisburg-essen-launch-namira-a-manually-curated-database-of-cancer-associated-micrornas-from-nearly-10000-publications 2026-08-08T17:48:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/royan-institute-and-university-of-duisburg-essen-launch-namira-a-manually-curated-database-of-cancer-associated-micrornas-from-nearly-10000-publications 2026-08-08T17:48:35+00:00 hourly 0.9 https://trial.medpath.com/news/a-biostatistician-s-step-by-step-method-for-evaluating-health-evidence 2026-08-08T17:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-biostatistician-s-step-by-step-method-for-evaluating-health-evidence 2026-08-08T17:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/viral-clearance-market-projected-to-reach-usd-4-8-billion-by-2036-driven-by-expanding-biologics-pipelines-and-updated-regulatory-guidance 2026-08-08T16:48:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viral-clearance-market-projected-to-reach-usd-4-8-billion-by-2036-driven-by-expanding-biologics-pipelines-and-updated-regulatory-guidance 2026-08-08T16:48:55+00:00 hourly 0.9 https://trial.medpath.com/news/immunotherapy-s-sting-in-the-tail-life-threatening-toxicity-persists-long-after-cancer-is-cured 2026-08-08T16:48:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunotherapy-s-sting-in-the-tail-life-threatening-toxicity-persists-long-after-cancer-is-cured 2026-08-08T16:48:54+00:00 hourly 0.9 https://trial.medpath.com/news/targeting-the-m6a-writer-mettl3-shows-neuroprotective-potential-in-neuroinflammation 2026-08-08T16:48:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeting-the-m6a-writer-mettl3-shows-neuroprotective-potential-in-neuroinflammation 2026-08-08T16:48:17+00:00 hourly 0.9 https://trial.medpath.com/news/biogen-extends-felzartamab-kidney-transplant-rejection-trial-into-four-year-long-term-safety-study 2026-08-08T15:51:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biogen-extends-felzartamab-kidney-transplant-rejection-trial-into-four-year-long-term-safety-study 2026-08-08T15:51:18+00:00 hourly 0.9 https://trial.medpath.com/news/cell-based-therapy-shows-functional-improvement-in-sjogren-s-syndrome-patient-with-severe-neurological-complications 2026-08-08T15:51:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-based-therapy-shows-functional-improvement-in-sjogren-s-syndrome-patient-with-severe-neurological-complications 2026-08-08T15:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/global-optogenetics-actuators-and-sensors-market-to-reach-usd-4-2-billion-by-2036-driven-by-neuroscience-research-and-federal-funding 2026-08-08T15:49:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-optogenetics-actuators-and-sensors-market-to-reach-usd-4-2-billion-by-2036-driven-by-neuroscience-research-and-federal-funding 2026-08-08T15:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-researchers-advance-blood-based-biomarker-testing-for-early-alzheimer-s-detection-identifying-disease-up-to-a-decade-before-symptoms 2026-08-08T15:49:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-researchers-advance-blood-based-biomarker-testing-for-early-alzheimer-s-detection-identifying-disease-up-to-a-decade-before-symptoms 2026-08-08T15:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/salmonella-outbreak-linked-to-mexican-jalapenos-sickens-345-across-27-states-triggers-usda-public-health-alert 2026-08-08T14:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/salmonella-outbreak-linked-to-mexican-jalapenos-sickens-345-across-27-states-triggers-usda-public-health-alert 2026-08-08T14:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/surrozen-submits-ind-for-szn-8141-a-bifunctional-wnt-agonist-vegf-antagonist-for-diabetic-macular-edema 2026-08-08T13:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/surrozen-submits-ind-for-szn-8141-a-bifunctional-wnt-agonist-vegf-antagonist-for-diabetic-macular-edema 2026-08-08T13:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/a-minister-s-cervical-cancer-journey-kiri-allan-on-diagnosis-fertility-loss-and-the-public-health-system 2026-08-08T13:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-minister-s-cervical-cancer-journey-kiri-allan-on-diagnosis-fertility-loss-and-the-public-health-system 2026-08-08T13:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/qc-ware-and-ionq-demonstrate-high-precision-hybrid-quantum-workflow-for-drug-discovery 2026-08-08T13:47:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qc-ware-and-ionq-demonstrate-high-precision-hybrid-quantum-workflow-for-drug-discovery 2026-08-08T13:47:34+00:00 hourly 0.9 https://trial.medpath.com/news/real-time-live-cell-observation-platform-could-transform-cancer-drug-discovery-and-precision-medicine 2026-08-08T12:48:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-time-live-cell-observation-platform-could-transform-cancer-drug-discovery-and-precision-medicine 2026-08-08T12:48:24+00:00 hourly 0.9 https://trial.medpath.com/news/mediar-therapeutics-enters-collaboration-with-ono-pharma-to-develop-novel-antibody-therapeutics-for-fibro-inflammatory-diseases 2026-08-08T11:47:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mediar-therapeutics-enters-collaboration-with-ono-pharma-to-develop-novel-antibody-therapeutics-for-fibro-inflammatory-diseases 2026-08-08T11:47:44+00:00 hourly 0.9 https://trial.medpath.com/news/ribox-therapeutics-secures-fda-ind-clearance-for-rxim002-the-first-circular-rna-based-in-vivo-car-t-therapy 2026-08-08T08:47:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ribox-therapeutics-secures-fda-ind-clearance-for-rxim002-the-first-circular-rna-based-in-vivo-car-t-therapy 2026-08-08T08:47:34+00:00 hourly 0.9 https://trial.medpath.com/news/tufts-csdd-benchmarking-study-commissioned-by-syneos-health-links-clinical-sourcing-models-to-trial-performance-and-quality 2026-08-08T08:47:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tufts-csdd-benchmarking-study-commissioned-by-syneos-health-links-clinical-sourcing-models-to-trial-performance-and-quality 2026-08-08T08:47:27+00:00 hourly 0.9 https://trial.medpath.com/news/quidelortho-cuts-2026-guidance-as-china-ivd-pricing-headwinds-and-soft-respiratory-season-weigh-on-diagnostics-business 2026-08-08T07:47:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quidelortho-cuts-2026-guidance-as-china-ivd-pricing-headwinds-and-soft-respiratory-season-weigh-on-diagnostics-business 2026-08-08T07:47:56+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-buy-ratings-on-vir-biotechnology-despite-widening-losses 2026-08-08T07:47:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analysts-maintain-buy-ratings-on-vir-biotechnology-despite-widening-losses 2026-08-08T07:47:27+00:00 hourly 0.9 https://trial.medpath.com/news/machine-learning-identifies-hnrnpa2b1-rpe-and-taf15-as-potential-stress-granule-related-biomarkers-for-childhood-asthma 2026-08-08T05:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/machine-learning-identifies-hnrnpa2b1-rpe-and-taf15-as-potential-stress-granule-related-biomarkers-for-childhood-asthma 2026-08-08T05:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/advanced-endometrial-cancer-pipeline-gains-momentum-as-adcs-immunotherapy-and-targeted-combinations-reshape-treatment 2026-08-08T03:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advanced-endometrial-cancer-pipeline-gains-momentum-as-adcs-immunotherapy-and-targeted-combinations-reshape-treatment 2026-08-08T03:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/david-sinclair-launches-lifespan-a-scientist-led-media-platform-as-first-human-epigenetic-reprogramming-trial-advances 2026-08-08T02:47:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/david-sinclair-launches-lifespan-a-scientist-led-media-platform-as-first-human-epigenetic-reprogramming-trial-advances 2026-08-08T02:47:43+00:00 hourly 0.9 https://trial.medpath.com/news/parkinson-s-drug-developers-shift-focus-to-neuroinflammation-as-alpha-synuclein-strategy-stalls 2026-08-07T23:47:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/parkinson-s-drug-developers-shift-focus-to-neuroinflammation-as-alpha-synuclein-strategy-stalls 2026-08-07T23:47:41+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-launches-legal-challenges-against-tirzepatide-generics 2026-08-07T23:47:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-launches-legal-challenges-against-tirzepatide-generics 2026-08-07T23:47:24+00:00 hourly 0.9 https://trial.medpath.com/news/navigating-clinical-trials-for-metastatic-bladder-cancer-a-guide-for-patients-and-clinicians 2026-08-07T22:52:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/navigating-clinical-trials-for-metastatic-bladder-cancer-a-guide-for-patients-and-clinicians 2026-08-07T22:52:08+00:00 hourly 0.9 https://trial.medpath.com/news/trump-administration-considers-executive-order-targeting-vaccines-and-autism-despite-scientific-consensus 2026-08-07T22:52:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trump-administration-considers-executive-order-targeting-vaccines-and-autism-despite-scientific-consensus 2026-08-07T22:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/insurers-seek-14-premium-hike-for-small-business-health-plans-in-2027-kff-analysis-finds 2026-08-07T21:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insurers-seek-14-premium-hike-for-small-business-health-plans-in-2027-kff-analysis-finds 2026-08-07T21:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/mmj-challenges-cms-over-medicare-program-funding-non-fda-approved-cannabinoid-products-while-demanding-fda-approval-pathway 2026-08-07T21:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mmj-challenges-cms-over-medicare-program-funding-non-fda-approved-cannabinoid-products-while-demanding-fda-approval-pathway 2026-08-07T21:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/renew-biotechnologies-publishes-proof-of-concept-study-on-neuron-derived-cfdna-methylation-signatures-for-alzheimer-s-parkinson-s-and-als 2026-08-07T21:48:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/renew-biotechnologies-publishes-proof-of-concept-study-on-neuron-derived-cfdna-methylation-signatures-for-alzheimer-s-parkinson-s-and-als 2026-08-07T21:48:43+00:00 hourly 0.9 https://trial.medpath.com/news/egetis-emcitate-nda-for-mct8-deficiency-advances-toward-september-28-2026-fda-decision 2026-08-07T21:48:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egetis-emcitate-nda-for-mct8-deficiency-advances-toward-september-28-2026-fda-decision 2026-08-07T21:48:14+00:00 hourly 0.9 https://trial.medpath.com/news/scalable-education-program-nearly-triples-skin-cancer-screening-rates-in-hct-survivors 2026-08-07T21:04:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scalable-education-program-nearly-triples-skin-cancer-screening-rates-in-hct-survivors 2026-08-07T21:04:44+00:00 hourly 0.9 https://trial.medpath.com/news/patient-derived-breast-cancer-organoids-validate-i-spy2-biomarkers-and-predict-treatment-response 2026-08-07T21:03:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-derived-breast-cancer-organoids-validate-i-spy2-biomarkers-and-predict-treatment-response 2026-08-07T21:03:56+00:00 hourly 0.9 https://trial.medpath.com/news/physicians-call-for-urgent-reforms-to-sustain-the-future-of-neonatal-critical-care 2026-08-07T19:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physicians-call-for-urgent-reforms-to-sustain-the-future-of-neonatal-critical-care 2026-08-07T19:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/dr-reddy-s-laboratories-terminates-distribution-agreement-with-novartis-india-following-shareholding-change 2026-08-07T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-reddy-s-laboratories-terminates-distribution-agreement-with-novartis-india-following-shareholding-change 2026-08-07T19:48:46+00:00 hourly 0.9 https://trial.medpath.com/news/asia-pacific-navigates-the-aging-indication-gap-through-three-distinct-routes-but-therapeutic-development-lags-behind-service-delivery 2026-08-07T19:48:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asia-pacific-navigates-the-aging-indication-gap-through-three-distinct-routes-but-therapeutic-development-lags-behind-service-delivery 2026-08-07T19:48:05+00:00 hourly 0.9 https://trial.medpath.com/news/greenstone-biosciences-secures-nih-r61-grant-to-develop-ipsc-and-ai-driven-therapies-for-dmd-cardiac-fibrosis 2026-08-07T17:52:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/greenstone-biosciences-secures-nih-r61-grant-to-develop-ipsc-and-ai-driven-therapies-for-dmd-cardiac-fibrosis 2026-08-07T17:52:45+00:00 hourly 0.9 https://trial.medpath.com/news/revelation-biosciences-secures-fda-agreement-for-adaptive-phase-2-3-trial-of-gemini-in-acute-kidney-injury 2026-08-07T17:52:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/revelation-biosciences-secures-fda-agreement-for-adaptive-phase-2-3-trial-of-gemini-in-acute-kidney-injury 2026-08-07T17:52:44+00:00 hourly 0.9 https://trial.medpath.com/news/micot-pharma-s-mt200605-hits-phase-ii-primary-endpoint-in-acute-ischemic-stroke-offering-first-in-class-multi-stage-neuroprotection 2026-08-07T17:51:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/micot-pharma-s-mt200605-hits-phase-ii-primary-endpoint-in-acute-ischemic-stroke-offering-first-in-class-multi-stage-neuroprotection 2026-08-07T17:51:42+00:00 hourly 0.9 https://trial.medpath.com/news/transcenta-sells-hangzhou-cdmo-plant-to-wuxi-biologics-for-rmb-190-million-then-licenses-hicb-platform-back-to-the-buyer 2026-08-07T17:51:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/transcenta-sells-hangzhou-cdmo-plant-to-wuxi-biologics-for-rmb-190-million-then-licenses-hicb-platform-back-to-the-buyer 2026-08-07T17:51:18+00:00 hourly 0.9 https://trial.medpath.com/news/sucla2-usp10-gene-interaction-may-predict-breast-cancer-metastasis-risk-and-treatment-benefit 2026-08-07T17:51:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sucla2-usp10-gene-interaction-may-predict-breast-cancer-metastasis-risk-and-treatment-benefit 2026-08-07T17:51:08+00:00 hourly 0.9 https://trial.medpath.com/news/priovant-initiates-phase-3-beacon-trial-of-brepocitinib-in-cutaneous-sarcoidosis-following-breakthrough-therapy-designation 2026-08-07T17:49:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/priovant-initiates-phase-3-beacon-trial-of-brepocitinib-in-cutaneous-sarcoidosis-following-breakthrough-therapy-designation 2026-08-07T17:49:37+00:00 hourly 0.9 https://trial.medpath.com/news/post-translational-modifications-orchestrate-cd8-t-cell-exhaustion-from-signal-initiation-to-epigenetic-locking 2026-08-07T17:49:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/post-translational-modifications-orchestrate-cd8-t-cell-exhaustion-from-signal-initiation-to-epigenetic-locking 2026-08-07T17:49:17+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-emergency-use-authorization-for-drug-to-prevent-new-world-screwworm-in-multiple-species 2026-08-07T17:49:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-emergency-use-authorization-for-drug-to-prevent-new-world-screwworm-in-multiple-species 2026-08-07T17:49:10+00:00 hourly 0.9 https://trial.medpath.com/news/intrathecal-morphine-pump-transforms-stage-iv-bowel-cancer-patient-s-life-moving-her-off-palliative-care 2026-08-07T17:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intrathecal-morphine-pump-transforms-stage-iv-bowel-cancer-patient-s-life-moving-her-off-palliative-care 2026-08-07T17:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/sunshine-biopharma-launches-generic-amoxicillin-in-canada-targeting-4-9-billion-global-market 2026-08-07T17:47:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sunshine-biopharma-launches-generic-amoxicillin-in-canada-targeting-4-9-billion-global-market 2026-08-07T17:47:26+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-acquires-alesta-therapeutics-and-its-hypophosphatasia-drug-ale1-in-275m-deal 2026-08-07T16:48:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-acquires-alesta-therapeutics-and-its-hypophosphatasia-drug-ale1-in-275m-deal 2026-08-07T16:48:10+00:00 hourly 0.9 https://trial.medpath.com/news/ligand-reports-32-royalty-revenue-growth-raises-eps-guidance-following-xoma-acquisition 2026-08-07T16:47:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ligand-reports-32-royalty-revenue-growth-raises-eps-guidance-following-xoma-acquisition 2026-08-07T16:47:31+00:00 hourly 0.9 https://trial.medpath.com/news/consistent-diabetes-medication-adherence-linked-to-fewer-heart-attacks-and-strokes-decade-long-danish-study-finds 2026-08-07T14:49:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/consistent-diabetes-medication-adherence-linked-to-fewer-heart-attacks-and-strokes-decade-long-danish-study-finds 2026-08-07T14:49:24+00:00 hourly 0.9 https://trial.medpath.com/news/google-deepmind-veterans-launch-discovery-loop-to-automate-scientific-discovery-with-ai 2026-08-07T14:48:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-deepmind-veterans-launch-discovery-loop-to-automate-scientific-discovery-with-ai 2026-08-07T14:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-ceo-reshma-kewalramani-leads-crispr-revolution-as-pharma-s-top-women-executives-reshape-the-industry 2026-08-07T14:48:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-ceo-reshma-kewalramani-leads-crispr-revolution-as-pharma-s-top-women-executives-reshape-the-industry 2026-08-07T14:48:28+00:00 hourly 0.9 https://trial.medpath.com/news/neurocrine-biosciences-launches-phase-i-trial-of-glp-1-gip-glucagon-triple-agonist-nbip-1968-for-obesity 2026-08-07T14:48:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurocrine-biosciences-launches-phase-i-trial-of-glp-1-gip-glucagon-triple-agonist-nbip-1968-for-obesity 2026-08-07T14:48:25+00:00 hourly 0.9 https://trial.medpath.com/news/new-mexico-court-orders-meta-to-pay-567-million-mandates-sweeping-teen-safety-overhaul-on-facebook-and-instagram 2026-08-07T14:48:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-mexico-court-orders-meta-to-pay-567-million-mandates-sweeping-teen-safety-overhaul-on-facebook-and-instagram 2026-08-07T14:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/zebrafish-study-reveals-bisphosphonates-may-block-pathological-spine-mineralization-opening-first-pharmacological-path-for-disc-degeneration 2026-08-07T13:47:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zebrafish-study-reveals-bisphosphonates-may-block-pathological-spine-mineralization-opening-first-pharmacological-path-for-disc-degeneration 2026-08-07T13:47:29+00:00 hourly 0.9 https://trial.medpath.com/news/health-catalyst-closes-vitalware-divestiture-and-retires-160-million-in-debt-to-refocus-on-healthcare-intelligence 2026-08-07T13:47:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-catalyst-closes-vitalware-divestiture-and-retires-160-million-in-debt-to-refocus-on-healthcare-intelligence 2026-08-07T13:47:25+00:00 hourly 0.9 https://trial.medpath.com/news/long-term-antidepressant-users-may-need-slower-hyperbolic-tapers-as-withdrawal-concerns-grow 2026-08-07T12:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/long-term-antidepressant-users-may-need-slower-hyperbolic-tapers-as-withdrawal-concerns-grow 2026-08-07T12:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/lz901-recombinant-herpes-zoster-vaccine-demonstrates-91-6-efficacy-in-phase-iii-trial-published-in-nature-communications 2026-08-07T11:47:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lz901-recombinant-herpes-zoster-vaccine-demonstrates-91-6-efficacy-in-phase-iii-trial-published-in-nature-communications 2026-08-07T11:47:32+00:00 hourly 0.9 https://trial.medpath.com/news/anthropic-reduces-claude-fable-5-biology-fallbacks-by-85-expands-access-for-clinicians-while-researchers-remain-locked-out 2026-08-07T10:49:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anthropic-reduces-claude-fable-5-biology-fallbacks-by-85-expands-access-for-clinicians-while-researchers-remain-locked-out 2026-08-07T10:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/riyadh-global-medical-biotechnology-summit-2026-to-convene-world-s-biotech-leaders-in-september 2026-08-07T10:48:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/riyadh-global-medical-biotechnology-summit-2026-to-convene-world-s-biotech-leaders-in-september 2026-08-07T10:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/dispatch-bio-doses-first-patient-in-phase-1-trial-of-disp-10-a-novel-synthetic-antigen-car-t-immunotherapy-for-advanced-gi-cancers-secures-fda-fast-track-designation 2026-08-07T06:48:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dispatch-bio-doses-first-patient-in-phase-1-trial-of-disp-10-a-novel-synthetic-antigen-car-t-immunotherapy-for-advanced-gi-cancers-secures-fda-fast-track-designation 2026-08-07T06:48:19+00:00 hourly 0.9 https://trial.medpath.com/news/kardium-s-globe-pulsed-field-system-secures-health-canada-approval-for-atrial-fibrillation-treatment 2026-08-07T05:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kardium-s-globe-pulsed-field-system-secures-health-canada-approval-for-atrial-fibrillation-treatment 2026-08-07T05:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/starling-oncology-reports-q2-2026-revenue-surge-raises-full-year-guidance-as-adjusted-ebitda-turns-positive 2026-08-07T04:52:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/starling-oncology-reports-q2-2026-revenue-surge-raises-full-year-guidance-as-adjusted-ebitda-turns-positive 2026-08-07T04:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/exobiosphere-secures-eur1m-non-dilutive-funding-to-scale-space-based-drug-discovery-platform 2026-08-07T04:52:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/exobiosphere-secures-eur1m-non-dilutive-funding-to-scale-space-based-drug-discovery-platform 2026-08-07T04:52:56+00:00 hourly 0.9 https://trial.medpath.com/news/ai-and-genetics-converge-to-identify-novel-wnk2-inhibitor-as-potential-disease-modifying-osteoarthritis-therapy 2026-08-07T04:52:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-and-genetics-converge-to-identify-novel-wnk2-inhibitor-as-potential-disease-modifying-osteoarthritis-therapy 2026-08-07T04:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/energenesis-biomedical-and-taiwan-tanabe-seiyaku-enter-joint-development-agreement-for-diabetic-foot-ulcer-candidate-energi-f703dfu 2026-08-07T04:52:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/energenesis-biomedical-and-taiwan-tanabe-seiyaku-enter-joint-development-agreement-for-diabetic-foot-ulcer-candidate-energi-f703dfu 2026-08-07T04:52:15+00:00 hourly 0.9 https://trial.medpath.com/news/steris-announces-600-million-center-of-excellence-in-north-carolina-for-infection-prevention-chemistries 2026-08-07T04:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/steris-announces-600-million-center-of-excellence-in-north-carolina-for-infection-prevention-chemistries 2026-08-07T04:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/sydney-towle-content-creator-who-documented-cholangiocarcinoma-journey-dies-at-26 2026-08-07T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sydney-towle-content-creator-who-documented-cholangiocarcinoma-journey-dies-at-26 2026-08-07T04:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/nearly-10-million-americans-with-untreated-high-blood-pressure-could-benefit-from-medication-under-new-guidelines 2026-08-07T03:53:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nearly-10-million-americans-with-untreated-high-blood-pressure-could-benefit-from-medication-under-new-guidelines 2026-08-07T03:53:09+00:00 hourly 0.9 https://trial.medpath.com/news/analysts-maintain-buy-ratings-on-fresenius-se-co-kgaa-amid-positive-insider-sentiment 2026-08-07T02:47:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analysts-maintain-buy-ratings-on-fresenius-se-co-kgaa-amid-positive-insider-sentiment 2026-08-07T02:47:27+00:00 hourly 0.9 https://trial.medpath.com/news/high-dose-vitamin-d3-fails-to-improve-outcomes-in-metastatic-colorectal-cancer-phase-3-trial-finds 2026-08-07T01:48:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-dose-vitamin-d3-fails-to-improve-outcomes-in-metastatic-colorectal-cancer-phase-3-trial-finds 2026-08-07T01:48:03+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-gene-editing-creates-hypoallergenic-beagles-in-first-of-its-kind-study 2026-08-07T01:47:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-gene-editing-creates-hypoallergenic-beagles-in-first-of-its-kind-study 2026-08-07T01:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/natera-reports-record-signatera-volumes-in-q2-2026-raises-guidance-on-mrd-market-momentum 2026-08-07T00:47:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natera-reports-record-signatera-volumes-in-q2-2026-raises-guidance-on-mrd-market-momentum 2026-08-07T00:47:45+00:00 hourly 0.9 https://trial.medpath.com/news/uab-translational-and-molecular-sciences-t32-training-program-renewed-by-nih-for-five-years-with-expanded-trainee-slots 2026-08-06T23:48:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uab-translational-and-molecular-sciences-t32-training-program-renewed-by-nih-for-five-years-with-expanded-trainee-slots 2026-08-06T23:48:05+00:00 hourly 0.9 https://trial.medpath.com/news/florida-invests-2-million-to-expand-fiu-s-functional-precision-oncology-program-for-treatment-resistant-cancers 2026-08-06T23:47:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/florida-invests-2-million-to-expand-fiu-s-functional-precision-oncology-program-for-treatment-resistant-cancers 2026-08-06T23:47:59+00:00 hourly 0.9 https://trial.medpath.com/news/recode-therapeutics-secures-cystic-fibrosis-foundation-funding-launches-gene-editing-collaboration-and-names-heather-clark-as-ceo 2026-08-06T22:54:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recode-therapeutics-secures-cystic-fibrosis-foundation-funding-launches-gene-editing-collaboration-and-names-heather-clark-as-ceo 2026-08-06T22:54:02+00:00 hourly 0.9 https://trial.medpath.com/news/v-foundation-awards-1-million-grant-to-cu-anschutz-for-infant-all-research-targeting-menin-inhibition 2026-08-06T22:53:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/v-foundation-awards-1-million-grant-to-cu-anschutz-for-infant-all-research-targeting-menin-inhibition 2026-08-06T22:53:43+00:00 hourly 0.9 https://trial.medpath.com/news/mainehealth-lincoln-hospital-transitions-labor-and-delivery-to-regional-model-preserving-prenatal-and-gynecologic-care-locally 2026-08-06T22:53:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mainehealth-lincoln-hospital-transitions-labor-and-delivery-to-regional-model-preserving-prenatal-and-gynecologic-care-locally 2026-08-06T22:53:27+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-trained-on-dna-creates-16-novel-viruses-raising-both-therapeutic-promise-and-biosecurity-alarms 2026-08-06T22:53:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-trained-on-dna-creates-16-novel-viruses-raising-both-therapeutic-promise-and-biosecurity-alarms 2026-08-06T22:53:22+00:00 hourly 0.9 https://trial.medpath.com/news/nafdac-issues-public-alert-over-counterfeit-forxiga-dapagliflozin-circulating-in-nigeria 2026-08-06T22:52:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nafdac-issues-public-alert-over-counterfeit-forxiga-dapagliflozin-circulating-in-nigeria 2026-08-06T22:52:55+00:00 hourly 0.9 https://trial.medpath.com/news/mercy-earns-klas-arch-collaborative-level-6-pinnacle-recognition-for-physician-ehr-experience 2026-08-06T21:48:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mercy-earns-klas-arch-collaborative-level-6-pinnacle-recognition-for-physician-ehr-experience 2026-08-06T21:48:02+00:00 hourly 0.9 https://trial.medpath.com/news/aclaris-therapeutics-receives-fda-fast-track-designation-for-modzatinib-in-moderate-to-severe-lichen-planus 2026-08-06T21:47:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aclaris-therapeutics-receives-fda-fast-track-designation-for-modzatinib-in-moderate-to-severe-lichen-planus 2026-08-06T21:47:59+00:00 hourly 0.9 https://trial.medpath.com/news/end-of-life-doulas-non-medical-companions-bridging-autonomy-and-care-in-cancer-patients-final-days 2026-08-06T21:47:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/end-of-life-doulas-non-medical-companions-bridging-autonomy-and-care-in-cancer-patients-final-days 2026-08-06T21:47:32+00:00 hourly 0.9 https://trial.medpath.com/news/ucsf-study-reveals-fat-tissue-fibrosis-drives-hidden-diabetes-risk-in-non-obese-hiv-patients 2026-08-06T21:47:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucsf-study-reveals-fat-tissue-fibrosis-drives-hidden-diabetes-risk-in-non-obese-hiv-patients 2026-08-06T21:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/first-complete-diploid-human-genome-ushers-in-new-era-of-personalized-medicine 2026-08-06T20:50:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-complete-diploid-human-genome-ushers-in-new-era-of-personalized-medicine 2026-08-06T20:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/scholar-rock-advances-apitegromab-toward-september-30-pdufa-date-as-first-muscle-targeted-therapy-for-sma 2026-08-06T20:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/scholar-rock-advances-apitegromab-toward-september-30-pdufa-date-as-first-muscle-targeted-therapy-for-sma 2026-08-06T20:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/doj-seeks-permanent-injunction-against-nevada-s-steiner-biotechnology-over-adulterated-dental-devices 2026-08-06T20:49:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/doj-seeks-permanent-injunction-against-nevada-s-steiner-biotechnology-over-adulterated-dental-devices 2026-08-06T20:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/bone-resorption-and-constipation-predict-higher-tenapanor-dose-requirements-in-dialysis-patients-with-hyperphosphatemia 2026-08-06T20:48:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bone-resorption-and-constipation-predict-higher-tenapanor-dose-requirements-in-dialysis-patients-with-hyperphosphatemia 2026-08-06T20:48:57+00:00 hourly 0.9 https://trial.medpath.com/news/il-6-receptor-blockers-show-promise-for-preventing-relapses-in-rare-autoimmune-neurological-disorder-mogad 2026-08-06T20:48:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/il-6-receptor-blockers-show-promise-for-preventing-relapses-in-rare-autoimmune-neurological-disorder-mogad 2026-08-06T20:48:12+00:00 hourly 0.9 https://trial.medpath.com/news/psychiatrists-testify-lindsay-clancy-showed-no-signs-of-psychosis-before-children-s-deaths 2026-08-06T18:48:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/psychiatrists-testify-lindsay-clancy-showed-no-signs-of-psychosis-before-children-s-deaths 2026-08-06T18:48:22+00:00 hourly 0.9 https://trial.medpath.com/news/creative-medical-receives-u-s-patent-allowance-for-exosome-based-type-1-diabetes-immunotherapy 2026-08-06T18:47:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/creative-medical-receives-u-s-patent-allowance-for-exosome-based-type-1-diabetes-immunotherapy 2026-08-06T18:47:38+00:00 hourly 0.9 https://trial.medpath.com/news/sk-biopharm-settles-us-patent-suit-over-xcopri-reinforcing-long-term-market-exclusivity 2026-08-06T17:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sk-biopharm-settles-us-patent-suit-over-xcopri-reinforcing-long-term-market-exclusivity 2026-08-06T17:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/ensysce-biosciences-acquires-cy-biopharma-secures-up-to-77-million-to-advance-orphan-designated-crps-therapy 2026-08-06T17:48:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ensysce-biosciences-acquires-cy-biopharma-secures-up-to-77-million-to-advance-orphan-designated-crps-therapy 2026-08-06T17:48:09+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-study-reveals-macrophage-dysfunction-not-absence-drives-aggressive-skin-cancer-in-immunosuppressed-patients 2026-08-06T17:47:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-study-reveals-macrophage-dysfunction-not-absence-drives-aggressive-skin-cancer-in-immunosuppressed-patients 2026-08-06T17:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/tarsus-to-acquire-alkeus-pharmaceuticals-for-up-to-800-million-securing-late-stage-stargardt-disease-drug-gildeuretinol 2026-08-06T16:51:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarsus-to-acquire-alkeus-pharmaceuticals-for-up-to-800-million-securing-late-stage-stargardt-disease-drug-gildeuretinol 2026-08-06T16:51:40+00:00 hourly 0.9 https://trial.medpath.com/news/northwest-biotherapeutics-signs-mou-with-spimaco-to-bring-dcvax-l-personalized-immunotherapy-for-glioblastoma-to-saudi-arabia 2026-08-06T16:51:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/northwest-biotherapeutics-signs-mou-with-spimaco-to-bring-dcvax-l-personalized-immunotherapy-for-glioblastoma-to-saudi-arabia 2026-08-06T16:51:31+00:00 hourly 0.9 https://trial.medpath.com/news/mathematical-biomarkers-predict-prostate-cancer-outcomes-in-adaptive-therapy 2026-08-06T16:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mathematical-biomarkers-predict-prostate-cancer-outcomes-in-adaptive-therapy 2026-08-06T16:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/risk-adapted-frameworks-reshape-pediatric-neuroblastoma-care-new-review-shows 2026-08-06T16:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risk-adapted-frameworks-reshape-pediatric-neuroblastoma-care-new-review-shows 2026-08-06T16:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/sonablate-and-eleven-ventures-forge-200-million-strategic-alliance-to-advance-ai-powered-therapeutic-ultrasound-globally 2026-08-06T15:48:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sonablate-and-eleven-ventures-forge-200-million-strategic-alliance-to-advance-ai-powered-therapeutic-ultrasound-globally 2026-08-06T15:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/lifemine-therapeutics-raises-263m-to-advance-novel-calcineurin-inhibitor-life-001-for-organ-transplant-rejection 2026-08-06T15:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lifemine-therapeutics-raises-263m-to-advance-novel-calcineurin-inhibitor-life-001-for-organ-transplant-rejection 2026-08-06T15:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-s-gene-therapy-pcrx-201-shows-durable-two-year-benefit-in-knee-osteoarthritis-phase-1-data-published-in-annals-of-the-rheumatic-diseases 2026-08-06T14:47:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-s-gene-therapy-pcrx-201-shows-durable-two-year-benefit-in-knee-osteoarthritis-phase-1-data-published-in-annals-of-the-rheumatic-diseases 2026-08-06T14:47:27+00:00 hourly 0.9 https://trial.medpath.com/news/tenax-therapeutics-phase-3-level-trial-of-tnx-103-fails-to-meet-primary-endpoint-in-ph-hfpef 2026-08-06T14:47:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tenax-therapeutics-phase-3-level-trial-of-tnx-103-fails-to-meet-primary-endpoint-in-ph-hfpef 2026-08-06T14:47:23+00:00 hourly 0.9 https://trial.medpath.com/news/generate-biomedicines-gb-0895-shows-durable-6-month-biomarker-suppression-in-phase-1-supporting-6-month-sc-dosing-in-severe-asthma 2026-08-06T13:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/generate-biomedicines-gb-0895-shows-durable-6-month-biomarker-suppression-in-phase-1-supporting-6-month-sc-dosing-in-severe-asthma 2026-08-06T13:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/medicare-part-d-protected-classes-see-58-initial-rejection-rate-despite-coverage-protections 2026-08-06T13:48:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medicare-part-d-protected-classes-see-58-initial-rejection-rate-despite-coverage-protections 2026-08-06T13:48:53+00:00 hourly 0.9 https://trial.medpath.com/news/carvolix-secures-eur30m-structured-debt-financing-from-claret-capital-to-accelerate-ai-driven-cardiovascular-robotics 2026-08-06T12:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carvolix-secures-eur30m-structured-debt-financing-from-claret-capital-to-accelerate-ai-driven-cardiovascular-robotics 2026-08-06T12:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/windrose-health-investors-recapitalizes-verified-clinical-trials-appoints-howard-miller-as-ceo-to-accelerate-growth 2026-08-06T12:01:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/windrose-health-investors-recapitalizes-verified-clinical-trials-appoints-howard-miller-as-ceo-to-accelerate-growth 2026-08-06T12:01:30+00:00 hourly 0.9 https://trial.medpath.com/news/actimed-therapeutics-reacquires-global-rights-to-s-oxprenolol-after-faraday-pharmaceuticals-collapse 2026-08-06T12:01:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actimed-therapeutics-reacquires-global-rights-to-s-oxprenolol-after-faraday-pharmaceuticals-collapse 2026-08-06T12:01:04+00:00 hourly 0.9 https://trial.medpath.com/news/kodiak-sciences-completes-enrollment-in-first-pivotal-cohort-of-phase-3-peak-trial-for-ksi-101-in-macular-edema-secondary-to-inflammation 2026-08-06T12:01:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kodiak-sciences-completes-enrollment-in-first-pivotal-cohort-of-phase-3-peak-trial-for-ksi-101-in-macular-edema-secondary-to-inflammation 2026-08-06T12:01:03+00:00 hourly 0.9 https://trial.medpath.com/news/vedanta-biosciences-secures-60-million-to-advance-phase-3-microbiome-therapy-ve303-for-recurrent-c-difficile-infection 2026-08-06T12:00:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vedanta-biosciences-secures-60-million-to-advance-phase-3-microbiome-therapy-ve303-for-recurrent-c-difficile-infection 2026-08-06T12:00:40+00:00 hourly 0.9 https://trial.medpath.com/news/neutrophil-derived-il-4-drives-spinal-cord-regeneration-in-zebrafish-study-finds 2026-08-06T12:00:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neutrophil-derived-il-4-drives-spinal-cord-regeneration-in-zebrafish-study-finds 2026-08-06T12:00:39+00:00 hourly 0.9 https://trial.medpath.com/news/xencor-reports-q2-2026-results-and-advances-xmab819-xmab541-and-xmab942-clinical-programs 2026-08-06T11:59:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xencor-reports-q2-2026-results-and-advances-xmab819-xmab541-and-xmab942-clinical-programs 2026-08-06T11:59:09+00:00 hourly 0.9 https://trial.medpath.com/news/evotec-and-odyssey-therapeutics-enter-ai-enabled-r-d-collaboration-to-discover-novel-therapies-for-autoimmune-and-inflammatory-diseases 2026-08-06T10:47:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evotec-and-odyssey-therapeutics-enter-ai-enabled-r-d-collaboration-to-discover-novel-therapies-for-autoimmune-and-inflammatory-diseases 2026-08-06T10:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/msf-launches-dengue-response-project-in-tegucigalpa-as-honduras-faces-escalating-outbreak 2026-08-06T10:47:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msf-launches-dengue-response-project-in-tegucigalpa-as-honduras-faces-escalating-outbreak 2026-08-06T10:47:51+00:00 hourly 0.9 https://trial.medpath.com/news/senhwa-s-cx-5461-reaches-immuno-oncology-milestone-as-first-multicenter-combination-trial-with-pd-1-inhibitor-receives-tfda-clearance 2026-08-06T10:47:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senhwa-s-cx-5461-reaches-immuno-oncology-milestone-as-first-multicenter-combination-trial-with-pd-1-inhibitor-receives-tfda-clearance 2026-08-06T10:47:47+00:00 hourly 0.9 https://trial.medpath.com/news/clarivate-scales-agentic-ai-across-cortellis-portfolio-to-accelerate-drug-development-decisions 2026-08-06T09:47:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clarivate-scales-agentic-ai-across-cortellis-portfolio-to-accelerate-drug-development-decisions 2026-08-06T09:47:25+00:00 hourly 0.9 https://trial.medpath.com/news/molecular-editing-unlocks-new-chemical-space-in-pyridine-based-drug-discovery 2026-08-06T05:49:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/molecular-editing-unlocks-new-chemical-space-in-pyridine-based-drug-discovery 2026-08-06T05:49:46+00:00 hourly 0.9 https://trial.medpath.com/news/chewing-gum-made-from-lablab-beans-reduces-hpv-by-93-and-nearly-eradicates-cancer-linked-oral-bacteria 2026-08-06T02:49:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chewing-gum-made-from-lablab-beans-reduces-hpv-by-93-and-nearly-eradicates-cancer-linked-oral-bacteria 2026-08-06T02:49:33+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-moves-to-shut-kentucky-organ-procurement-organization-citing-persistent-safety-failures 2026-08-06T02:49:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-moves-to-shut-kentucky-organ-procurement-organization-citing-persistent-safety-failures 2026-08-06T02:49:08+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-nominates-ai-designed-ism9077-as-first-in-class-preclinical-candidate-for-ocular-and-inflammatory-diseases 2026-08-06T01:50:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-nominates-ai-designed-ism9077-as-first-in-class-preclinical-candidate-for-ocular-and-inflammatory-diseases 2026-08-06T01:50:37+00:00 hourly 0.9 https://trial.medpath.com/news/cellfiber-and-tidewave-bio-partner-to-evaluate-3d-manufacturing-for-off-the-shelf-solid-tumor-immunotherapy 2026-08-06T01:50:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellfiber-and-tidewave-bio-partner-to-evaluate-3d-manufacturing-for-off-the-shelf-solid-tumor-immunotherapy 2026-08-06T01:50:33+00:00 hourly 0.9 https://trial.medpath.com/news/canada-to-build-267-million-medical-countermeasures-lab-in-winnipeg-to-bolster-pandemic-preparedness 2026-08-06T01:50:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/canada-to-build-267-million-medical-countermeasures-lab-in-winnipeg-to-bolster-pandemic-preparedness 2026-08-06T01:50:06+00:00 hourly 0.9 https://trial.medpath.com/news/massive-genomic-study-identifies-fnip1-skinny-gene-mutation-that-mimics-glp-1-drug-effects 2026-08-05T23:50:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/massive-genomic-study-identifies-fnip1-skinny-gene-mutation-that-mimics-glp-1-drug-effects 2026-08-05T23:50:54+00:00 hourly 0.9 https://trial.medpath.com/news/imdelltra-bite-therapy-shows-game-changer-results-in-small-cell-lung-cancer-patients 2026-08-05T23:50:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imdelltra-bite-therapy-shows-game-changer-results-in-small-cell-lung-cancer-patients 2026-08-05T23:50:22+00:00 hourly 0.9 https://trial.medpath.com/news/phase-1-trial-shows-fridge-free-tetanus-diphtheria-vaccine-matches-standard-boosters-in-safety-and-immunogenicity 2026-08-05T23:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-1-trial-shows-fridge-free-tetanus-diphtheria-vaccine-matches-standard-boosters-in-safety-and-immunogenicity 2026-08-05T23:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/us-australia-collaboration-aims-to-accelerate-early-stage-clinical-trials-and-strengthen-american-biotech-competitiveness 2026-08-05T23:50:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-australia-collaboration-aims-to-accelerate-early-stage-clinical-trials-and-strengthen-american-biotech-competitiveness 2026-08-05T23:50:14+00:00 hourly 0.9 https://trial.medpath.com/news/evonik-breaks-ground-on-eur80-million-biotech-expansion-at-slovakian-fermas-site 2026-08-05T23:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evonik-breaks-ground-on-eur80-million-biotech-expansion-at-slovakian-fermas-site 2026-08-05T23:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-weight-loss-jabs-linked-to-rising-gallstone-disease-and-gallbladder-surgery-as-unapproved-retatrutide-fuels-black-market 2026-08-05T23:49:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-weight-loss-jabs-linked-to-rising-gallstone-disease-and-gallbladder-surgery-as-unapproved-retatrutide-fuels-black-market 2026-08-05T23:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-to-acquire-apogee-therapeutics-for-135-11-per-share-in-landmark-immunology-deal 2026-08-05T22:53:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-to-acquire-apogee-therapeutics-for-135-11-per-share-in-landmark-immunology-deal 2026-08-05T22:53:29+00:00 hourly 0.9 https://trial.medpath.com/news/cu-anschutz-rheumatologists-expand-access-to-care-through-econsults-and-off-campus-clinics 2026-08-05T21:50:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cu-anschutz-rheumatologists-expand-access-to-care-through-econsults-and-off-campus-clinics 2026-08-05T21:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/uk-launches-mrc-centre-of-research-excellence-to-pioneer-mitochondrial-genome-therapeutics 2026-08-05T21:50:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-launches-mrc-centre-of-research-excellence-to-pioneer-mitochondrial-genome-therapeutics 2026-08-05T21:50:24+00:00 hourly 0.9 https://trial.medpath.com/news/single-cell-and-spatial-omics-take-center-stage-at-2026-2027-international-conferences 2026-08-05T21:49:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-cell-and-spatial-omics-take-center-stage-at-2026-2027-international-conferences 2026-08-05T21:49:01+00:00 hourly 0.9 https://trial.medpath.com/news/dronabinol-eliminates-ptsd-nightmares-in-over-one-third-of-patients-in-phase-iii-trial 2026-08-05T20:51:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dronabinol-eliminates-ptsd-nightmares-in-over-one-third-of-patients-in-phase-iii-trial 2026-08-05T20:51:11+00:00 hourly 0.9 https://trial.medpath.com/news/dick-vitale-reports-immunotherapy-effectively-wiping-out-cancer-in-fifth-diagnosis 2026-08-05T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dick-vitale-reports-immunotherapy-effectively-wiping-out-cancer-in-fifth-diagnosis 2026-08-05T20:49:12+00:00 hourly 0.9 https://trial.medpath.com/news/nextel-medical-to-acquire-xycota-biosciences-gaining-exosome-delivered-neuro-restoration-platform-with-pending-fda-orphan-drug-designation 2026-08-05T19:52:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextel-medical-to-acquire-xycota-biosciences-gaining-exosome-delivered-neuro-restoration-platform-with-pending-fda-orphan-drug-designation 2026-08-05T19:52:14+00:00 hourly 0.9 https://trial.medpath.com/news/marvel-biosciences-mb-204-reverses-behavioural-and-cognitive-deficits-in-fragile-x-mouse-model-marking-third-preclinical-asd-success 2026-08-05T19:51:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marvel-biosciences-mb-204-reverses-behavioural-and-cognitive-deficits-in-fragile-x-mouse-model-marking-third-preclinical-asd-success 2026-08-05T19:51:45+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-advances-first-ai-discovered-neuroscience-target-with-genentech-lowers-cash-burn-guidance 2026-08-05T19:51:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-advances-first-ai-discovered-neuroscience-target-with-genentech-lowers-cash-burn-guidance 2026-08-05T19:51:19+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-microbiome-transplant-shows-promise-as-novel-treatment-for-peanut-allergy-in-first-in-human-trial 2026-08-05T18:50:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-microbiome-transplant-shows-promise-as-novel-treatment-for-peanut-allergy-in-first-in-human-trial 2026-08-05T18:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/human-cancer-model-initiative-publishes-665-next-generation-patient-derived-organoid-models-spanning-25-cancer-types 2026-08-05T18:50:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/human-cancer-model-initiative-publishes-665-next-generation-patient-derived-organoid-models-spanning-25-cancer-types 2026-08-05T18:50:12+00:00 hourly 0.9 https://trial.medpath.com/news/uk-biobank-study-links-ckm-syndrome-stages-to-stepwise-cancer-risk-via-distinct-immune-metabolic-pathways 2026-08-05T18:50:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-biobank-study-links-ckm-syndrome-stages-to-stepwise-cancer-risk-via-distinct-immune-metabolic-pathways 2026-08-05T18:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/nice-breast-cancer-referral-criteria-miss-95-of-at-risk-women-under-50-study-finds 2026-08-05T17:49:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nice-breast-cancer-referral-criteria-miss-95-of-at-risk-women-under-50-study-finds 2026-08-05T17:49:56+00:00 hourly 0.9 https://trial.medpath.com/news/next-generation-3d-cancer-models-reveal-clinically-relevant-gene-dependencies-missed-by-traditional-cell-lines 2026-08-05T17:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-generation-3d-cancer-models-reveal-clinically-relevant-gene-dependencies-missed-by-traditional-cell-lines 2026-08-05T17:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/lemaitre-vascular-reports-record-q2-2026-results-driven-by-artegraft-global-expansion 2026-08-05T17:49:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lemaitre-vascular-reports-record-q2-2026-results-driven-by-artegraft-global-expansion 2026-08-05T17:49:50+00:00 hourly 0.9 https://trial.medpath.com/news/payam-saadai-appointed-chief-of-pediatric-general-thoracic-and-fetal-surgery-at-uc-davis-health 2026-08-05T17:49:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/payam-saadai-appointed-chief-of-pediatric-general-thoracic-and-fetal-surgery-at-uc-davis-health 2026-08-05T17:49:45+00:00 hourly 0.9 https://trial.medpath.com/news/fc-optimized-gitr-antibody-boosts-cd4-t-cell-dendritic-cell-teamwork-against-tumors 2026-08-05T17:49:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fc-optimized-gitr-antibody-boosts-cd4-t-cell-dendritic-cell-teamwork-against-tumors 2026-08-05T17:49:37+00:00 hourly 0.9 https://trial.medpath.com/news/nsf-awards-utoledo-nearly-1m-for-high-resolution-maldi-ms-to-advance-drug-development-and-disease-research 2026-08-05T17:49:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nsf-awards-utoledo-nearly-1m-for-high-resolution-maldi-ms-to-advance-drug-development-and-disease-research 2026-08-05T17:49:11+00:00 hourly 0.9 https://trial.medpath.com/news/charles-river-laboratories-raises-2026-profit-forecast-on-strengthening-biotech-demand 2026-08-05T16:55:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/charles-river-laboratories-raises-2026-profit-forecast-on-strengthening-biotech-demand 2026-08-05T16:55:28+00:00 hourly 0.9 https://trial.medpath.com/news/aacr-launches-first-of-its-kind-phase-ii-trial-testing-organ-preservation-in-gastroesophageal-cancer 2026-08-05T16:54:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aacr-launches-first-of-its-kind-phase-ii-trial-testing-organ-preservation-in-gastroesophageal-cancer 2026-08-05T16:54:46+00:00 hourly 0.9 https://trial.medpath.com/news/expedition-therapeutics-raises-115m-series-b-to-advance-first-global-phase-2-trial-of-dpp1-inhibitor-in-copd 2026-08-05T16:52:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expedition-therapeutics-raises-115m-series-b-to-advance-first-global-phase-2-trial-of-dpp1-inhibitor-in-copd 2026-08-05T16:52:42+00:00 hourly 0.9 https://trial.medpath.com/news/light-activated-nanorobots-enable-targeted-phototherapy-for-breast-cancer 2026-08-05T16:52:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/light-activated-nanorobots-enable-targeted-phototherapy-for-breast-cancer 2026-08-05T16:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/federal-circuit-affirms-non-infringement-ruling-clearing-path-for-aveva-s-generic-ztlido-launch 2026-08-05T16:51:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/federal-circuit-affirms-non-infringement-ruling-clearing-path-for-aveva-s-generic-ztlido-launch 2026-08-05T16:51:44+00:00 hourly 0.9 https://trial.medpath.com/news/when-diagnosis-waits-lung-cancer-pet-access-and-global-oncology 2026-08-05T16:51:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/when-diagnosis-waits-lung-cancer-pet-access-and-global-oncology 2026-08-05T16:51:17+00:00 hourly 0.9 https://trial.medpath.com/news/mindfulness-based-therapy-for-opioid-misuse-delivers-12-in-savings-for-every-1-spent-uc-san-diego-analysis-finds 2026-08-05T16:51:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mindfulness-based-therapy-for-opioid-misuse-delivers-12-in-savings-for-every-1-spent-uc-san-diego-analysis-finds 2026-08-05T16:51:07+00:00 hourly 0.9 https://trial.medpath.com/news/fda-weighs-approval-of-moderna-s-mrna-flu-vaccine-mflusiva-amid-political-scrutiny 2026-08-05T16:50:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-weighs-approval-of-moderna-s-mrna-flu-vaccine-mflusiva-amid-political-scrutiny 2026-08-05T16:50:03+00:00 hourly 0.9 https://trial.medpath.com/news/breast-milk-s-extraordinary-biology-how-hmos-iga-and-dha-shape-infant-gut-and-brain-development 2026-08-05T15:49:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-milk-s-extraordinary-biology-how-hmos-iga-and-dha-shape-infant-gut-and-brain-development 2026-08-05T15:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-and-abbvie-to-present-at-the-2026-wells-fargo-healthcare-conference 2026-08-05T14:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-and-abbvie-to-present-at-the-2026-wells-fargo-healthcare-conference 2026-08-05T14:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/eton-pharmaceuticals-licenses-u-s-rights-to-asn-001-a-late-stage-topical-therapy-for-moderate-infantile-hemangiomas 2026-08-05T14:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eton-pharmaceuticals-licenses-u-s-rights-to-asn-001-a-late-stage-topical-therapy-for-moderate-infantile-hemangiomas 2026-08-05T14:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/novel-two-part-drug-puts-cancer-cells-under-extreme-metabolic-stress-by-hijacking-sugar-and-blocking-fat 2026-08-05T14:49:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-two-part-drug-puts-cancer-cells-under-extreme-metabolic-stress-by-hijacking-sugar-and-blocking-fat 2026-08-05T14:49:26+00:00 hourly 0.9 https://trial.medpath.com/news/reckitt-s-mucinex-12hr-cold-fever-multi-symptom-receives-fda-approval-as-first-otc-cold-flu-innovation-in-14-years 2026-08-05T14:49:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/reckitt-s-mucinex-12hr-cold-fever-multi-symptom-receives-fda-approval-as-first-otc-cold-flu-innovation-in-14-years 2026-08-05T14:49:25+00:00 hourly 0.9 https://trial.medpath.com/news/expedition-therapeutics-raises-115m-series-b-as-dpp1-inhibitor-expd-101-enters-phase-2-copd-trial 2026-08-05T13:49:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expedition-therapeutics-raises-115m-series-b-as-dpp1-inhibitor-expd-101-enters-phase-2-copd-trial 2026-08-05T13:49:04+00:00 hourly 0.9 https://trial.medpath.com/news/cullinan-therapeutics-reports-53-7-million-q2-loss-missing-analyst-expectations 2026-08-05T12:49:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cullinan-therapeutics-reports-53-7-million-q2-loss-missing-analyst-expectations 2026-08-05T12:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-links-cyp2c19-genotype-to-specific-ssri-side-effects-and-discontinuation 2026-08-05T11:49:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-links-cyp2c19-genotype-to-specific-ssri-side-effects-and-discontinuation 2026-08-05T11:49:36+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-of-atezolizumab-plus-bevacizumab-yields-nearly-40-response-rate-in-peritoneal-mesothelioma 2026-08-05T11:49:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-of-atezolizumab-plus-bevacizumab-yields-nearly-40-response-rate-in-peritoneal-mesothelioma 2026-08-05T11:49:27+00:00 hourly 0.9 https://trial.medpath.com/news/obsidian-therapeutics-enrolls-first-patient-in-registration-enabling-cohort-for-amsoki-cel-til-therapy-in-advanced-melanoma 2026-08-05T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/obsidian-therapeutics-enrolls-first-patient-in-registration-enabling-cohort-for-amsoki-cel-til-therapy-in-advanced-melanoma 2026-08-05T11:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-q2-2026-pharma-portfolio-renewal-gains-traction-as-nubeqa-and-kerendia-surge-66 2026-08-05T10:04:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-q2-2026-pharma-portfolio-renewal-gains-traction-as-nubeqa-and-kerendia-surge-66 2026-08-05T10:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/zydus-lifesciences-wins-usfda-approval-for-generic-indocyanine-green-injection-with-competitive-generic-therapy-designation 2026-08-05T10:04:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zydus-lifesciences-wins-usfda-approval-for-generic-indocyanine-green-injection-with-competitive-generic-therapy-designation 2026-08-05T10:04:17+00:00 hourly 0.9 https://trial.medpath.com/news/cell-and-gene-therapy-advances-outpace-healthcare-system-readiness 2026-08-05T10:04:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-and-gene-therapy-advances-outpace-healthcare-system-readiness 2026-08-05T10:04:14+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-initiates-phase-1-trial-of-oral-stat6-degrader-sar448272-triggering-10m-milestone-payment-to-nurix 2026-08-05T08:49:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-initiates-phase-1-trial-of-oral-stat6-degrader-sar448272-triggering-10m-milestone-payment-to-nurix 2026-08-05T08:49:45+00:00 hourly 0.9 https://trial.medpath.com/news/sandoz-q2-sales-beat-expectations-as-biosimilars-surge-22-ushering-in-a-golden-decade 2026-08-05T07:51:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sandoz-q2-sales-beat-expectations-as-biosimilars-surge-22-ushering-in-a-golden-decade 2026-08-05T07:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/ai-is-helping-solve-the-intricate-genetic-puzzle-of-schizophrenia 2026-08-05T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-is-helping-solve-the-intricate-genetic-puzzle-of-schizophrenia 2026-08-05T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dragon-boat-paddling-offers-physical-and-psychosocial-healing-for-cancer-survivors 2026-08-05T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dragon-boat-paddling-offers-physical-and-psychosocial-healing-for-cancer-survivors 2026-08-05T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/blood-filtering-technique-for-cholesterol-also-removes-forever-chemicals-and-microplastics-study-finds 2026-08-05T03:50:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-filtering-technique-for-cholesterol-also-removes-forever-chemicals-and-microplastics-study-finds 2026-08-05T03:50:11+00:00 hourly 0.9 https://trial.medpath.com/news/tadalafil-long-term-use-linked-to-22-higher-glaucoma-risk-in-men-with-enlarged-prostates 2026-08-05T02:50:05+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tadalafil-long-term-use-linked-to-22-higher-glaucoma-risk-in-men-with-enlarged-prostates 2026-08-05T02:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/chipotle-pulls-jalapenos-as-health-officials-investigate-salmonella-outbreak 2026-08-05T02:49:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chipotle-pulls-jalapenos-as-health-officials-investigate-salmonella-outbreak 2026-08-05T02:49:40+00:00 hourly 0.9 https://trial.medpath.com/news/iqvia-and-medera-forge-strategic-collaboration-to-accelerate-cardiac-gene-therapy-and-human-based-drug-discovery 2026-08-05T00:51:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iqvia-and-medera-forge-strategic-collaboration-to-accelerate-cardiac-gene-therapy-and-human-based-drug-discovery 2026-08-05T00:51:30+00:00 hourly 0.9 https://trial.medpath.com/news/tumor-like-tissue-microenvironments-could-hold-clues-to-curing-hiv-northwestern-study-finds 2026-08-04T23:50:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tumor-like-tissue-microenvironments-could-hold-clues-to-curing-hiv-northwestern-study-finds 2026-08-04T23:50:52+00:00 hourly 0.9 https://trial.medpath.com/news/breast-cancer-hijacks-immune-cells-to-recruit-tumor-fueling-nerves-ou-study-reveals 2026-08-04T21:52:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breast-cancer-hijacks-immune-cells-to-recruit-tumor-fueling-nerves-ou-study-reveals 2026-08-04T21:52:11+00:00 hourly 0.9 https://trial.medpath.com/news/blood-biomarker-amh-predicts-chemotherapy-benefit-in-premenopausal-women-with-hr-positive-breast-cancer 2026-08-04T20:53:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/blood-biomarker-amh-predicts-chemotherapy-benefit-in-premenopausal-women-with-hr-positive-breast-cancer 2026-08-04T20:53:28+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-label-extension-for-bavarian-nordic-s-imvanex-mpox-vaccine-to-children-aged-2-and-older 2026-08-04T19:50:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-label-extension-for-bavarian-nordic-s-imvanex-mpox-vaccine-to-children-aged-2-and-older 2026-08-04T19:50:34+00:00 hourly 0.9 https://trial.medpath.com/news/enzene-launches-nextm-end-to-end-partnership-model-to-democratize-biologics-manufacturing-worldwide 2026-08-04T19:50:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enzene-launches-nextm-end-to-end-partnership-model-to-democratize-biologics-manufacturing-worldwide 2026-08-04T19:50:28+00:00 hourly 0.9 https://trial.medpath.com/news/three-essential-medicines-classified-as-carcinogenic-by-iarc-experts-urge-continued-treatment-with-monitoring 2026-08-04T19:50:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-essential-medicines-classified-as-carcinogenic-by-iarc-experts-urge-continued-treatment-with-monitoring 2026-08-04T19:50:10+00:00 hourly 0.9 https://trial.medpath.com/news/university-of-chicago-medical-center-earns-u-s-news-best-hospital-honors-only-illinois-academic-medical-center-to-receive-community-access-designation 2026-08-04T18:49:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-of-chicago-medical-center-earns-u-s-news-best-hospital-honors-only-illinois-academic-medical-center-to-receive-community-access-designation 2026-08-04T18:49:06+00:00 hourly 0.9 https://trial.medpath.com/news/ladakh-set-to-become-india-s-first-region-to-complete-census-2027-by-september 2026-08-04T18:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ladakh-set-to-become-india-s-first-region-to-complete-census-2027-by-september 2026-08-04T18:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/insilico-medicine-uses-ai-to-map-molecular-landscape-and-identify-therapeutic-targets-for-rare-sinonasal-cancer 2026-08-04T17:50:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insilico-medicine-uses-ai-to-map-molecular-landscape-and-identify-therapeutic-targets-for-rare-sinonasal-cancer 2026-08-04T17:50:46+00:00 hourly 0.9 https://trial.medpath.com/news/3mdr-therapy-shows-promise-for-ptsd-with-traumatic-brain-injury-delivering-26-point-symptom-reduction 2026-08-04T17:50:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/3mdr-therapy-shows-promise-for-ptsd-with-traumatic-brain-injury-delivering-26-point-symptom-reduction 2026-08-04T17:50:42+00:00 hourly 0.9 https://trial.medpath.com/news/novel-mirna-129-based-therapy-achieves-over-95-tumor-shrinkage-in-preclinical-nsclc-model-halting-drug-resistance 2026-08-04T17:49:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-mirna-129-based-therapy-achieves-over-95-tumor-shrinkage-in-preclinical-nsclc-model-halting-drug-resistance 2026-08-04T17:49:55+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-names-tom-cavanaugh-to-lead-innovative-medicine-as-jennifer-taubert-retires-after-21-years 2026-08-04T16:51:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-names-tom-cavanaugh-to-lead-innovative-medicine-as-jennifer-taubert-retires-after-21-years 2026-08-04T16:51:24+00:00 hourly 0.9 https://trial.medpath.com/news/carsgen-s-allogeneic-bcma-car-t-ct0596-gains-nmpa-ind-approval-for-relapsed-refractory-multiple-myeloma 2026-08-04T16:50:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carsgen-s-allogeneic-bcma-car-t-ct0596-gains-nmpa-ind-approval-for-relapsed-refractory-multiple-myeloma 2026-08-04T16:50:52+00:00 hourly 0.9 https://trial.medpath.com/news/graymatters-health-taps-former-cigna-behavioral-health-executive-to-scale-payor-coverage-for-fda-cleared-prism-ptsd-therapy 2026-08-04T16:49:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/graymatters-health-taps-former-cigna-behavioral-health-executive-to-scale-payor-coverage-for-fda-cleared-prism-ptsd-therapy 2026-08-04T16:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/uhealth-achieves-historic-gains-in-2026-2027-u-s-news-best-hospitals-rankings-led-by-25th-consecutive-no-1-for-ophthalmology 2026-08-04T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uhealth-achieves-historic-gains-in-2026-2027-u-s-news-best-hospitals-rankings-led-by-25th-consecutive-no-1-for-ophthalmology 2026-08-04T16:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/cirrus-therapeutics-secures-14-7m-seed-financing-and-seri-collaboration-to-advance-ocular-gene-therapy-for-geographic-atrophy 2026-08-04T15:50:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cirrus-therapeutics-secures-14-7m-seed-financing-and-seri-collaboration-to-advance-ocular-gene-therapy-for-geographic-atrophy 2026-08-04T15:50:23+00:00 hourly 0.9 https://trial.medpath.com/news/asp-isotopes-alpa-theranostics-to-advance-nanobody-powered-radiopharmaceuticals-into-clinical-trials-within-12-months 2026-08-04T15:50:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/asp-isotopes-alpa-theranostics-to-advance-nanobody-powered-radiopharmaceuticals-into-clinical-trials-within-12-months 2026-08-04T15:50:19+00:00 hourly 0.9 https://trial.medpath.com/news/research-use-recombinant-protein-market-projected-to-reach-1-55-billion-by-2031-driven-by-expanding-drug-discovery-pipelines 2026-08-04T15:50:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/research-use-recombinant-protein-market-projected-to-reach-1-55-billion-by-2031-driven-by-expanding-drug-discovery-pipelines 2026-08-04T15:50:04+00:00 hourly 0.9 https://trial.medpath.com/news/entropy-neurodynamics-secures-ethics-approval-for-world-first-72-patient-basket-trial-of-iv-psilocin-across-eight-neuropsychiatric-indications 2026-08-04T15:49:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/entropy-neurodynamics-secures-ethics-approval-for-world-first-72-patient-basket-trial-of-iv-psilocin-across-eight-neuropsychiatric-indications 2026-08-04T15:49:03+00:00 hourly 0.9 https://trial.medpath.com/news/lower-vitamin-d-linked-to-mood-and-cognitive-impairment-in-adults-over-85-with-diabetes 2026-08-04T15:49:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lower-vitamin-d-linked-to-mood-and-cognitive-impairment-in-adults-over-85-with-diabetes 2026-08-04T15:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/cnd-life-sciences-secures-growth-financing-led-by-s-curve-partners-to-expand-syn-one-test-platform-for-neurodegenerative-diagnostics 2026-08-04T15:48:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cnd-life-sciences-secures-growth-financing-led-by-s-curve-partners-to-expand-syn-one-test-platform-for-neurodegenerative-diagnostics 2026-08-04T15:48:52+00:00 hourly 0.9 https://trial.medpath.com/news/ever-supreme-s-allogeneic-solid-tumor-car-t-car001-advances-to-phase-iia-targets-2028-taiwan-provisional-approval 2026-08-04T14:48:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ever-supreme-s-allogeneic-solid-tumor-car-t-car001-advances-to-phase-iia-targets-2028-taiwan-provisional-approval 2026-08-04T14:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/hss-extends-record-breaking-streak-with-17th-consecutive-no-1-orthopedics-ranking-in-u-s-news-world-report 2026-08-04T13:51:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hss-extends-record-breaking-streak-with-17th-consecutive-no-1-orthopedics-ranking-in-u-s-news-world-report 2026-08-04T13:51:51+00:00 hourly 0.9 https://trial.medpath.com/news/risvodetinib-demonstrates-disease-modifying-biomarker-reversal-in-parkinson-s-disease-phase-2-trial 2026-08-04T13:51:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/risvodetinib-demonstrates-disease-modifying-biomarker-reversal-in-parkinson-s-disease-phase-2-trial 2026-08-04T13:51:32+00:00 hourly 0.9 https://trial.medpath.com/news/university-at-buffalo-faculty-spinouts-secure-nearly-16-million-in-2025-advancing-diagnostics-ai-and-therapeutics 2026-08-04T13:51:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/university-at-buffalo-faculty-spinouts-secure-nearly-16-million-in-2025-advancing-diagnostics-ai-and-therapeutics 2026-08-04T13:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/evexta-bio-and-roche-ink-clinical-collaboration-to-evaluate-rupitasertib-plus-giredestrant-in-esr1-mutated-metastatic-breast-cancer 2026-08-04T12:49:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evexta-bio-and-roche-ink-clinical-collaboration-to-evaluate-rupitasertib-plus-giredestrant-in-esr1-mutated-metastatic-breast-cancer 2026-08-04T12:49:29+00:00 hourly 0.9 https://trial.medpath.com/news/marengo-nominates-first-tristar-drug-candidate-with-ipsen-appoints-t-cell-engager-expert-saso-cemerski 2026-08-04T12:49:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marengo-nominates-first-tristar-drug-candidate-with-ipsen-appoints-t-cell-engager-expert-saso-cemerski 2026-08-04T12:49:13+00:00 hourly 0.9 https://trial.medpath.com/news/mosaic-therapeutics-appoints-dr-allison-jeynes-as-chair-of-the-board-ahead-of-clinical-stage-transition 2026-08-04T10:49:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mosaic-therapeutics-appoints-dr-allison-jeynes-as-chair-of-the-board-ahead-of-clinical-stage-transition 2026-08-04T10:49:37+00:00 hourly 0.9 https://trial.medpath.com/news/inizio-launches-connected-insights-to-transform-global-medical-information-into-strategic-intelligence 2026-08-04T09:50:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inizio-launches-connected-insights-to-transform-global-medical-information-into-strategic-intelligence 2026-08-04T09:50:15+00:00 hourly 0.9 https://trial.medpath.com/news/the-second-act-of-thalidomide-from-teratogen-to-the-foundation-of-targeted-protein-degradation 2026-08-04T07:11:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-second-act-of-thalidomide-from-teratogen-to-the-foundation-of-targeted-protein-degradation 2026-08-04T07:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/pathos-ai-licenses-experimental-triple-negative-breast-cancer-drug-from-china-s-alphamab-in-125-million-deal 2026-08-04T07:10:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pathos-ai-licenses-experimental-triple-negative-breast-cancer-drug-from-china-s-alphamab-in-125-million-deal 2026-08-04T07:10:11+00:00 hourly 0.9 https://trial.medpath.com/news/sanofi-s-menquadfi-wins-eu-approval-for-infants-from-six-weeks-of-age-against-invasive-meningococcal-disease 2026-08-04T07:08:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sanofi-s-menquadfi-wins-eu-approval-for-infants-from-six-weeks-of-age-against-invasive-meningococcal-disease 2026-08-04T07:08:54+00:00 hourly 0.9 https://trial.medpath.com/news/colorado-teacher-marks-10-years-in-complete-remission-after-pioneering-car-t-cell-therapy-at-nebraska-medical-center 2026-08-04T07:08:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/colorado-teacher-marks-10-years-in-complete-remission-after-pioneering-car-t-cell-therapy-at-nebraska-medical-center 2026-08-04T07:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/fda-assigns-class-i-recall-to-impella-heart-pump-introducer-kits-over-bleeding-risk 2026-08-04T06:08:36+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-assigns-class-i-recall-to-impella-heart-pump-introducer-kits-over-bleeding-risk 2026-08-04T06:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/iol-chemicals-pharmaceuticals-concludes-39th-agm-approves-fy26-financials-and-director-re-appointment 2026-08-04T04:09:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iol-chemicals-pharmaceuticals-concludes-39th-agm-approves-fy26-financials-and-director-re-appointment 2026-08-04T04:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/korean-drugmakers-pivot-to-digital-healthcare-as-generic-price-cuts-squeeze-profitability 2026-08-04T03:07:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/korean-drugmakers-pivot-to-digital-healthcare-as-generic-price-cuts-squeeze-profitability 2026-08-04T03:07:41+00:00 hourly 0.9 https://trial.medpath.com/news/nicotine-free-vapes-found-to-contain-nicotine-and-unverified-analogues-exposing-regulatory-blind-spot-in-south-korea 2026-08-04T00:09:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nicotine-free-vapes-found-to-contain-nicotine-and-unverified-analogues-exposing-regulatory-blind-spot-in-south-korea 2026-08-04T00:09:13+00:00 hourly 0.9 https://trial.medpath.com/news/cellular-basis-of-hfpef-abnormal-lipids-and-the-emerging-role-of-electronegative-vldl-v5 2026-08-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cellular-basis-of-hfpef-abnormal-lipids-and-the-emerging-role-of-electronegative-vldl-v5 2026-08-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/former-openai-exec-fidji-simo-launches-chroniclebio-to-tackle-pots-and-chronic-diseases-using-ai-driven-subtyping 2026-08-03T23:08:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/former-openai-exec-fidji-simo-launches-chroniclebio-to-tackle-pots-and-chronic-diseases-using-ai-driven-subtyping 2026-08-03T23:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/three-daily-servings-of-full-fat-dairy-show-no-adverse-metabolic-effects-in-overweight-adults-study-finds 2026-08-03T22:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/three-daily-servings-of-full-fat-dairy-show-no-adverse-metabolic-effects-in-overweight-adults-study-finds 2026-08-03T22:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/lingo1-targeted-antibody-drug-conjugates-show-preclinical-efficacy-and-tolerability-in-ewing-sarcoma-models 2026-08-03T22:08:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lingo1-targeted-antibody-drug-conjugates-show-preclinical-efficacy-and-tolerability-in-ewing-sarcoma-models 2026-08-03T22:08:22+00:00 hourly 0.9